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Abstract 
Background: Patients with irritable bowel syndrome (IBS) have often attributed certain 
foods as common triggers for the worsening of gastrointestinal (GI) symptoms. However, 
the role of diet in the management of IBS symptoms has not clearly been established. 
Recently, the effect of fibre, gluten and FODMAPs (Fermentable Oligosaccharides, 
Disaccharides, Monosaccharides And Polyols) on gastrointestinal symptoms have been 
investigated with conflicting results. Questionnaires are commonly used to collect 
information about participant’s symptoms, while the most accurate method to measure an 
individual’s dietary intake is a multiple-day food record. Despite this, there is 
surprisingly no validated food and symptom diary for IBS to investigate the role of diet 
upon IBS symptoms.  
Objective: The aim of this pilot study is to investigate the relationship between the 
consumption of fibre, gluten, and FODMAPs and subsequent gastrointestinal symptoms 
in IBS participants to determine the predictive validity of the food and gastrointestinal 
symptom diary. This will be achieved by validating the real-time gastrointestinal 
symptom scales incorporated into a food and gastrointestinal symptom diary for IBS.  
Methods: A three-day estimated food and real-time gastrointestinal symptom diary was 
completed by 51 participants with IBS, along with several legacy instruments. All food 
items consumed were entered for analysis into the food and nutrient analysis program; 
Kai-culator. To validate the real-time gastrointestinal symptoms, the relationship between 
the symptoms and the legacy instruments were examined using Spearman’s correlation 
coefficients. The legacy instruments used are the PROMIS (Patient Reported Outcome 
Measurement Information System) GI scales, the GSRS (Gastrointestinal Symptom 
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Rating Scale), and the IBS-QOL (Irritable Bowel Syndrome Quality of Life). Further 
statistical analysis investigated the relationship between food intake and gastrointestinal 
symptoms.  
Results: The real-time gastrointestinal symptom scales showed moderate correlations for 
the severity and length of time the symptoms were experienced with the PROMIS GI 
scales legacy instrument (0.31-0.64, p<0.05), and moderate correlations for the severity 
of the symptoms experienced with the GSRS legacy instrument (0.28-0.46, p<0.05), with 
the exception of the subscale constipation for both instruments. The IBS-QOL legacy 
instrument showed moderate correlations with the real-time gastrointestinal symptom 
abdominal bloating (0.33-0.39, p<0.05) only. Food intake did not differ significantly 
according to IBS subtype (fibre p=0.785, gluten p=0.270, and FODMAPs p=0.743). 
Higher FODMAP intake was associated with more severe abdominal bloating (p<0.05). 
Consuming lesser amounts of fibre was associated with more severe abdominal pain prior 
to a bowel motion, and with more severe straining to have the bowel motion (both 
p<0.05).   
Conclusion: The novel real-time gastrointestinal symptom scales show reasonable 
reliability to measure gastrointestinal symptoms as they occur in IBS participants. 
Incorporated into a food and symptom diary, this enables a deeper understanding of the 
association between the consumption of specific food and nutrients and the generation of 
gastrointestinal symptoms, providing a valid instrument to increase the knowledge and 
options for the treatment of IBS symptoms.  
Key words: irritable bowel syndrome, fibre, gluten, FODMAPs, gastrointestinal 
symptoms, validity, food and symptom diary  
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Preface 
 
The COMFORT study is a prospective observational case control study of adults with 
irritable bowel syndrome and controls undergoing a colonoscopy in Christchurch.  
The aim of this thesis is to pilot test and assess the validity of the food and symptom 
diary in a sample of IBS participants. If validity is acceptable, the diary will then be used 
in the COMFORT study. The relationship between the intake of fibre, gluten, FODMAPs 
and the IBS symptoms reported in the diary, a measure of predictive validity, is examined 
in this thesis.  
As part of this thesis, the candidate: 
- Was responsible for recruiting 70% of participants in Dunedin and Christchurch, 
including putting up recruitment posters and contacting organisations with 
networks through which participants could be recruited.  
- Was responsible for co-ordinating participant participation, including booking 
appointment rooms, sending reminder emails, and making follow-up phone calls. 
- Completed data entry of 51 three-day estimated food records, 51 three-day real-
time gastrointestinal symptoms records, and entered participant responses to the 
following legacy instruments: the GSRS, the PROMIS GI scales, and the IBS-
QOL.  
- Compiled food groups for gluten and FODMAP containing foods determined by 
individual ingredient components and allocated all food items consumed 
accordingly.  
- Completed some of the basic statistical analyses presented in this thesis.  
- Wrote this thesis.  
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1. Introduction 
Irritable bowel syndrome (IBS) is a highly prevalent functional bowel disorder 
characterised by recurrent abdominal pain associated with defaecation or a change in 
bowel habits, abdominal bloating, and abdominal distension (1). There are no structural 
abnormalities or validated biomarkers for diagnosis; thus, diagnosis is made based on the 
presentation of symptoms.  
 
The Rome criteria are used universally for diagnosis of IBS (2). To further assess 
gastrointestinal symptoms in IBS there are many validated questionnaires. Typically, IBS 
symptom severity, frequency, and bothersomeness are retrospectively assessed in these 
questionnaires (3-5). This retrospective method relies on participant’s long-term recall of 
their symptoms and, due to the fluctuation of symptoms throughout the day, may not 
accurately depict symptom frequency (6).  
 
The relative validity of a questionnaire (determining if the questionnaire accurately 
measures what it aims to measure) can be measured by content, criterion, or construct 
validity (7, 8). Construct validity can be evaluated by comparison of the questionnaire 
measuring a concept to a previously validated legacy questionnaire(s) measuring the 
same or similar concepts (9). The predictive validity of an instrument can be determined 
by investigating how well an instrument is associated with variables of interest.  
 
In recent years, there has been growing interest in the role of diet in the treatment of IBS 
symptoms. Studies have shown that many IBS patients attribute the intake of certain food 
items with the onset and worsening of their gastrointestinal symptoms (10, 11). 
Traditionally, the food items caffeine, spicy foods, alcohol, and fatty foods have been 
reported as triggers for IBS symptoms, with limiting and conflicting evidence (12). 
Modifying the intake of carbohydrate-rich foods, in particular those food items 
containing the nutrients fibre, gluten, and FODMAPs have recently come into the 
spotlight. While fibre has been a mainstay in the treatment of IBS symptoms for decades, 
the efficacy of both insoluble and soluble fibre has been controversial (13-17). The 
exclusion of gluten from the diet is necessary in treating Coeliac’s disease, however its 
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efficacy in treating IBS symptoms remains uncertain (18-21). Reducing FODMAPs 
consumption has been investigated primarily for treating gastrointestinal symptoms and 
has shown promising results (22-24).  
 
One important area of inquiry, therefore, is to increase the understanding of options for 
the treatment of IBS symptoms, by investigating the role of diet in the management of 
IBS symptoms. Detailed studies investigating the relationship between food and nutrients 
and symptoms in IBS are surprisingly few, in part due to the controversial role of diet in 
treating the symptoms of IBS.  
 
In order to elucidate which food or nutrients may be associated with the development of 
gastrointestinal symptoms, one must first be able to determine the food consumption of 
the participants.  The quantitative dietary assessment method of multiple-day food 
records, despite the high respondent burden, will provide the most accurate information 
of an individual’s habitual dietary intake (25). To concurrently record the food intake and 
gastrointestinal symptoms in IBS patients, a symptom scale can be incorporated into a 
multiple-day food diary. 
 
The aim of this study was to pilot test and validate a real-time food and real-time 
gastrointestinal symptom diary for the purpose of determining the predictive validity of 
the diary by examining the relationship between fibre, gluten and FODMAP consumption 
and gastrointestinal IBS symptoms in adults with IBS.  
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2. Literature Review  
The electronic databases ‘MEDLINE’, ‘SCOPUS’, and ‘CINAHL’ were used to identify 
relevant studies for this literature review. The search terms used were: ‘irritable bowel 
syndrome’, ‘diagnosis’, ‘gastrointestinal symptoms’, ‘questionnaire’, ‘validity’, 
‘nutrition’, ‘diet’, ‘food and symptom diary’, ‘fibre’, ‘gluten’, and ‘FODMAPs’. They 
were searched independently and in different combinations; only full-length articles in 
English were considered. References from pertinent articles identified by database 
searches were also reviewed to search for more studies.  
2.1 Irritable bowel syndrome 
Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal (GI) disorder 
characterised by symptoms of abdominal pain, changes in bowel habits, abdominal 
bloating and distension (1). It is further classified in to IBS-D (IBS with diarrhoea), IBS-
C (IBS with constipation), IBS-M (IBS with mixed bowel habits) and IBS-U (IBS 
unclassified) based on a patient’s predominant bowel patterns (1).  
2.1.1 Prevalence  
 
Irritable bowel syndrome has a global prevalence of 11.2% varying between  1.1% - 
45.0% according to the geographic location and the diagnostic criteria used (26). The 
diagnostic criteria will be discussed in section 2.1.4. IBS is more prevalent in women and 
in persons aged younger than 50 years, regardless of the diagnostic criteria used  (26). 
The prevalence of IBS remains stable over time (26).  
IBS prevalence in New Zealand (NZ) was assessed in a cross-sectional birth cohort at 26 
years of age, finding the IBS prevalence to be 10.3% (27, 28). The NZ prevalence of IBS 
is higher in women (12.6%) than men (8.0%) (27). There are no data available 
concerning the prevalence of IBS according to age or ethnic group in NZ. The prevalence 
of participants experiencing IBS symptoms in a NZ cohort of 50-year-old participants has 
also been assessed, finding that 76% of participants report experiencing at least one IBS 
symptom in the past 4 weeks (29).  
2.1.2 Diagnosis  
A traditional diagnosis of organic disease is typically made based on observations of 
anatomical or physiological abnormalities. Functional disorders such as IBS however 
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have no such abnormalities, and have been traditionally diagnosed by exclusion. An IBS 
diagnosis can now be made based on the presentation of symptoms in the absence of ‘red 
flags’ for organic gastrointestinal disease using diagnostic criteria (see section 2.1.4) and 
limited diagnostic testing (30, 31). People fulfilling IBS diagnostic criteria should have 
the following laboratory tests to exclude other diseases: full blood count, erythrocyte 
sedimentation rate, C-reactive protein, calprotectin, and antibody testing for coeliac 
disease (30). 
Organic diseases of the gastrointestinal tract include inflammatory bowel diseases, 
coeliac disease, colorectal cancer, and diverticulosis. ‘Red flag’ alarm features of these 
diseases not compatible with IBS include unintentional or unexplained weight loss, rectal 
bleeding, nocturnal or progressive abdominal pain, and laboratory abnormalities such as 
anaemia, elevated inflammatory markers, or electrolyte disturbances (30, 32). IBS 
patients presenting with any of these alarm features, a family history of colorectal cancer 
or inflammatory bowel disease, abdominal or rectal masses, or a late onset of symptoms 
(over 60 years old) will require further diagnostic testing  to rule out organic 
gastrointestinal disease (30, 32). These diagnostic tests may include colonoscopy or 
flexible sigmoidoscopy, twenty-four-hour stool collection, or radiology (32). Before the 
introduction of diagnostic criteria, patients presenting with IBS symptoms required these 
invasive diagnostic tests; but now diagnostic criteria for IBS can be used alone in patients 
with no alarm features, and no family history of colorectal cancer or inflammatory bowel 
disease (32).  
2.1.3 Aetiology and pathophysiology  
While the exact cause of IBS remains unknown, it appears to be a multifactorial disorder 
involving both host and environmental factors (1, 10). Possible patho-physiological 
mechanisms of IBS include altered gastrointestinal motility, visceral hypersensitivity, 
hyperalgesia, increased intestinal mucosal permeability, dysbiosis, dysregulated brain-gut 
interaction, and immune activation (1, 10, 33). 
2.1.4 Diagnostic criteria  
Diagnostic criteria for IBS have been developed to avoid the invasive diagnostic testing 
required to exclude organic gastrointestinal diseases (28, 34). The use of individual 
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symptoms to diagnose IBS have limited accuracy, such as abdominal pain, for which 
sensitivity is high at 90% but specificity low at 32% (35) and therefore criteria with a 
combination of symptoms have been developed (28, 34, 36).  
The Manning criteria were the first symptom based IBS diagnostic criteria to be 
developed, defined primarily to differentiate between IBS and organic gastrointestinal 
disease, in order to reduce diagnostic investigations for IBS patients (28).  
No threshold number of symptoms required for a positive diagnosis of IBS were 
recommended, therefore in the literature the presence of between two and four of the six 
Manning criteria symptoms listed in Figure 2.1 have been used to diagnose IBS, with the 
likelihood of IBS increasing in a patient presenting with more of the six symptoms (28, 
30).  
 
The Kruis score for diagnosing IBS includes a patient questionnaire (items about physical 
symptoms associated with IBS listed in Figure 2.2 and a patient history) and a clinician 
questionnaire (physical examination and some basic investigations into ‘red flag’ alarm 
features of organic disease – erythrocyte sedimentation rate and blood count) which are 
then both incorporated into a scoring system (34). The Kruis scoring system was 
developed to diagnose IBS in the absence of organic disease and to limit the diagnostic 
testing previously required to exclude organic disease. A score >44 is indicative of IBS, 
with characteristics of IBS having positive scores, and “red flags” having negative scores.   
Figure 2.2 Kruis score physical symptoms 
assessed (34) 
Figure 2.1 Manning criteria (28)       
 
The Manning and Kruis diagnostic criteria both require the presence of symptoms typical 
to IBS for a positive diagnosis. The Kruis score also requires these symptoms to be 
present for >2 years and to be present with no ‘red flags’ for gastrointestinal organic 
disease. The Manning criteria can adequately discern between IBS and organic 
gastrointestinal disease with a sensitivity of 58% and a specificity of 74% (37). The Kruis 
score has a sensitivity and specificity of 83% and 97%, respectively to diagnose IBS (34).  
1. Pain relieved by defecation 
2. Looser stools at onset of pain  
3. More frequent stools at pain onset 
4. Visible abdominal distension 
5. Passage of mucus 
6. Feeling of incomplete evacuation 
 
1. Abdominal pain 
2. Flatulence 
3. Irregularities of bowel movement 
4. Alternating bowel movements 
5. Pathological stool properties 
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The Rome criteria for diagnosis of IBS have since been established to provide uniformity 
and reproducibility, and are used universally in research, by clinicians, and in clinical 
trials to diagnose IBS (2, 31). An advantage of the Rome criteria is the ability to discern 
between IBS subtype, which was lacking in the Manning and Kruis criteria. Rome IV has 
a sensitivity of 62.7% and an excellent specificity of 97.1% to diagnose IBS (38). The 
most recent version, Rome IV, is detailed below (1). 
Figure 2.3 Rome IV diagnostic criteria for irritable bowel syndrome (1) 
2.2 Development and validation of questionnaires 
The first step in questionnaire development is to decide upon the research aim. To ensure 
a reliable and valid questionnaire is created, the variables to be collected, the audience, 
the method of collection, and the response format must all be considered during the 
content and wording design process (39).  Focus groups may be required to elucidate 
necessary items for the questionnaire (40). Pilot testing the questionnaire with the 
intended audience is essential to remove any flaws in the design (40, 41). The validity of 
the questionnaire can then be assessed.  
2.2.1 Methods to evaluate validity  
 
Validity is used to determine the degree to which a questionnaire accurately measures 
what it aims to measure. Absolute validity measures the extent to which an instrument 
exactly covers the concept it aims to measure while relative validity measures the extent 
to which an instrument measures a concept when compared to a previously validated 
measure of this same or similar concept (7) . In health, when the absolute validity of an 
instrument cannot be ascertained, three categories of relative validity testing are used; 
content, criterion, and construct validity (8).  
Content validity is the degree to which an instrument covers all important areas of 
Recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, 
associated with two or more of the following criteria: 
1. Related to defecation 
2. Associate with a change in frequency of stool 
3. Associated with a change in form (appearance) of stool 
 
* Criteria fulfilled for the last 3 months with symptom onset at least 6 months 
before diagnosis 
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interest that it intends to represent, and does not include irrelevant items (8, 9, 42, 43). 
Face validity, a type of content validity, assesses the extent to which an instrument 
appears to measure the items it intends to (9).  
Criterion validity is the degree to which scales from an instrument correlate with scales 
from a previously validated instrument (8, 9, 43, 44). These correlations can be evaluated 
by concurrent validity (administering the instruments at the same time to determine the 
instruments ability to distinguish between groups it should theoretically be able to) or 
predictive validity (administering the instrument at a specified time and administering the 
previously validated instrument in the future to determine the instruments ability to 
predict that which it should theoretically be able to) (9, 44). However, predictive validity 
has mainly been reported in the literature as it applies to psychometric testing. Predictive 
validity can also encapsulate the degree to which an instrument is associated with 
variables of interest.  
Construct validity determines the degree to which an instrument’s scales correlate to 
scales of another instrument and whether these correlations are consistent with 
theoretically derived hypotheses regarding the items being measured (8, 9, 43, 44).  The 
instrument scales and that of a previously validated instrument can correlate strongly 
(convergent validity) or weakly (discriminant validity).  
2.2.2 Commonly used questionnaires in IBS and their validity and reliability 
To determine the patient burden of IBS, many questionnaires have been developed and 
validated (3-5, 45-47). The Gastrointestinal Symptom Rating Scale (GSRS) was 
developed as a clinical rating scale for gastrointestinal symptoms due to the 
unsatisfactory reliability of the available scales, primarily to discern between IBS and 
peptic ulcer disease (3). The GSRS retrospectively assesses gastrointestinal symptoms 
from the prior week. The GSRS has been shown to be reliable and exhibits good validity 
(3, 48). Since the publication of the GSRS in 1988 there has been a breadth of new 
validated questionnaires assessing patient-reported gastrointestinal symptoms. Patient-
reported outcomes include items about the physical, emotional and social impacts of the 
disease.  These patient-reported outcome measures can be generic (for a range of 
different conditions) or condition specific. Researchers have become increasingly 
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interested in assessing the patient’s health related quality of life in recent years. However, 
as generic quality of life instruments are not sensitive and lack precision regarding 
patients’ disease specific health-related concerns and consequences, disease-targeted 
quality of life measures are preferred (49, 50). The IBS-QOL (Irritable Bowel Syndrome 
Quality of Life) questionnaire is the most extensively validated disease-specific quality of 
life measure for irritable bowel syndrome (51, 52). The IBS-QOL gathers information 
about the IBS patient’s quality of life during the prior month (5). However, most 
clinicians do not routinely administer patient-reported outcome measurements during 
consultations (51).  Considering this, a gastrointestinal specific instrument to measure 
patient-reported symptom and quality of life outcomes in both research and clinical care 
was designed and validated (4, 51, 53). This instrument is the PROMIS (Patient Reported 
Outcomes Measurement Information System) gastrointestinal symptom scales. These 
scales retrospectively collect physical, emotional and social data from the past 7 days. 
The PROMIS GI scales are reliable and exhibit good validity (4).  
The validation of the GSRS, the IBS-QOL questionnaire, and the PROMIS GI scales are 
discussed in Table 2.1. These legacy questionnaires all gather symptom information 
retrospectively, relying on patient recall to provide accurate information. IBS symptoms 
fluctuate throughout the day, therefore a method to gather symptom information 
concurrently is necessary. Despite the published associations between food and 
gastrointestinal symptoms in IBS, these legacy documents do not evaluate the association 
between food consumption and gastrointestinal symptoms.  
2.3 Irritable bowel syndrome and nutrition  
Up to 90% of IBS patients identify food as a trigger for their gastrointestinal symptoms 
(10, 11). As meals are consumed at various points throughout the day, this results in the 
fluctuation of symptoms throughout the day. Postprandial worsening of gastrointestinal 
symptoms typically occurs within 3 hours, with over 50% of IBS patients reporting their 
symptoms worsening within just 30 minutes of eating (54). IBS patients have a high 
prevalence of perceived food intolerances (54-56).  
 
The consumption of caffeine, spicy foods, alcohol, fatty foods, and carbohydrate-rich 
foods have long been thought to be associated with the worsening of gastrointestinal 
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symptoms (54, 55). There is limited evidence to support these observed and patient 
perceived food-related gastrointestinal symptoms in IBS patients (12). The potential 
mechanisms by which these foods may cause or exacerbate gastrointestinal symptoms in 
IBS are listed below.  
 
Caffeine increases gastric acid secretion and stimulates gastrointestinal motility which 
may cause diarrhoea (57, 58). Capsaicin is found in spicy foods and delays gastric 
emptying while accelerating overall gastrointestinal transit (59). Capsaicin also activates 
the TRPV1 receptor in the gastrointestinal tract which can cause abdominal pain (60). 
Alcohol affects gastrointestinal motility and intestinal absorption which may cause 
diarrhoea (61, 62). High fat/fried foods affect gastrointestinal motility via stimulation of 
the gastrocolic response and have been associated with causing the gastrointestinal 
symptoms of abdominal pain and gas (54, 63, 64).  
Carbohydrate-rich foods have been reported to influence gastrointestinal symptoms (54). 
Modifying fibre intake has traditionally been used to manage gastrointestinal symptoms, 
and more recently the role of gluten, and the consumption of FODMAPs (Fermentable 
Oligosaccharides, Disaccharides, Monosaccharides, And Polyols) as potential treatment 
options have been investigated (12, 22, 65).   
2.3.1 Fibre 
Dietary fibre is defined as a form of non-digestible carbohydrate, consisting mainly of 
non-starch polysaccharides, both soluble and insoluble fibre, and resistant starch (66, 67). 
The term dietary fibre does not incorporate FODMAPs (66). Traditionally dietary fibre 
has been used as a treatment option in irritable bowel syndrome due to its effect on 
gastrointestinal transit (65). However, the effectiveness of fibre to treat IBS symptoms 
remains uncertain due to conflicting research (13, 14). Fibre is used effectively to treat 
constipation due to its laxative properties, while studies have found that fibre may worsen 
the gastrointestinal symptoms of diarrhoea or bloating in IBS-D (14, 15). Fibre has been 
found to relieve constipation, abdominal discomfort, and bloating in IBS-C (16).  Soluble 
fibre supplements (such as psyllium and ispaghula) may alleviate gastrointestinal 
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Table 2.1 Commonly used questionnaires assessing gastrointestinal symptoms in irritable bowel syndrome 





(GSRS) (3, 48)  
 




3. Indigestion  
(4 items) 
4. Diarrhoea  
(3 items)  
5. Constipation  
(3 items) 
 
The GSRS has been validated in 
patients with gastroesophageal 
reflux disease.  
 
Content validity was not directly 
established.  
 
Validity was established using 
Pearson’s correlation coefficients 
to determine the correlations 
between the GSRS scales, the 
Medical Outcomes Study Short 
Form Quality of Life Questionnaire 
(SF-36) scales, and the 
Psychological General Well-Being 
(PGWB) scales.  
 
Construct validity by means of 
known groups discriminant validity 
was determined for the GSRS via 
comparison of GSRS scores before 
and after 6 weeks of treatment in 
responsive and non-responsive 
patients, as well as by comparison 
of symptom severity.   
 
 
Correlations between the GSRS scales, the SF-36 scales, and the PGWB scales 
 GSRS 
    Diarrhoea Constipation Abdominal Pain Indigestion Reflux 
SF-36      
Physical function -0.19* -0.24* -0.19* -0.14* -0.11* 
Role physical  -0.25* -0.21* -0.29* -0.19* -0.09 
Bodily pain -0.30* -0.29* -0.44* -0.31* -0.23* 
General health -0.31* -0.19* -0.31* -0.17* -0.15* 
Mental health -0.25* -0.30* -0.34* -0.25* -0.13 
Role emotional -0.22* -0.25* -0.31* -0.22* -0.12 
Vitality  -0.31* -0.20* -0.42* -0.26* -0.19* 
Social function -0.29* -0.23* -0.37* -0.29* -0.17* 
PGWB      
Total -0.31* -0.30* -0.43* -0.34* -0.21* 
Anxiety  -0.25* -0.29* -0.40* -0.32* -0.17* 
Depression -0.23* -0.29* -0.31* -0.25* -0.14 
Positive well-being -0.12 -0.09 -0.15 0.12 -0.12 
Behavioural control -0.18* -0.26* -0.29* -0.25* -0.16 
General health  -0.32* -0.27* -0.41* -0.31* 0.22* 






















  *p<0.0001.  
 
Statistically significant GSRS scores were detected between responders and non-responders after 6 
weeks of treatment. The mean GSRS scores change from baseline to 6 weeks were reduced in the 
respondent group. As symptom severity increased, so too did mean GSRS scores. These results were 
also statistically significant at the p<0.0001 level.  
 
All correlations between the GSRS and the SF-36 were statistically significant except for the GSRS 
scale reflux syndrome and the SF-36 scales role functions – physical, mental health, and role functions 
– emotional. Except for the PGWB positive well-being score, the GSRS scales diarrhoea syndrome, 
constipation syndrome, abdominal pain, and indigestion syndrome significantly correlated to the PGWB. 
The PGWB total score was significantly correlated to all GSRS scales. However, the GSRS reflux 
syndrome did not correlate to the PGWB scores of depression, positive well-being, and behavioural 
control. 
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Table 2.1 continued 
 










Scales (4)  
 
1. Belly pain        
(6 items) 
2. Constipation   
(9 items) 
3. Diarrhea          
(6 items) 
4. Disrupted 
swallowing     
(7 items) 
5. Bowel 
incontinence    
(4 items) 
6. Gas/bloating   
(12 items) 
7. Nausea/ 




reflux              
(13 items) 
Content validity was assessed by 
patient feedback regarding relevance 
of items, comprehension, perceptions 
about language and ambiguity.  
Construct validity was assessed 
using Pearson correlations between 
PROMIS GI symptom scales and the 
legacy instruments: 
• Visceral Sensitivity Index 
(VSI) 
• GSRS 
• PROMIS global physical 
health 
• EuroQOL 
Patients also completed an additional 
questionnaire as determined by their 
gastrointestinal disorder. These 
legacy scales and the PROMIS 
scales were predicted a priori to 
correlate significantly.  
Following feedback and discussions, items were revised as necessary and some additional items were 
added to establish content validity. 
 
Correlations of the PROMIS GI Scales with selected legacy instruments 
 VSI IBS-QOL GSRS 
Reflux Indigestion Belly Pain Diarrhoea Constipation 
PROMIS GI Scales        
Reflux 0.48 -0.25 0.68 0.55 0.57 0.36 0.45 
Swallow 0.43 -0.22 0.58 0.49 0.51 0.33 0.42 
Diarrhoea 0.56 -0.50 0.37 0.53 0.31 0.80 0.39 
Incontinence 0.57 -0.37 0.32 0.38 0.34 0.53 0.28 
Nausea/ Vomiting 0.53 -0.31 0.51 0.54 0.71 0.39 0.46 
Constipation 0.50 -0.32 0.40 0.53 0.50 0.36 0.77 
Abdominal Pain 0.66 -0.45 0.44 0.65 0.74 0.52 0.56 
Gas/ 
Bloating 
0.62 -0.53 0.45 0.76 0.64 0.45 0.60 
  All correlation coefficients are significant at the P<0.05 level 
Correlations of the PROMIS GI symptom scales, when compared to the legacy instruments, were 
statistically significant and in the expected direction as hypothesised.  
Irritable Bowel 
Syndrome 
Quality of Life 





1. Dysphoria        
(8 items) 
2. Interference 
with activity    
(7 items) 
3. Body image     
(4 items) 
4. Health worry   
(3 items) 
5. Food 
avoidance      
(3 items) 
Content validity was determined from 
literature review, clinician interviews, 
and IBS patient interviews. 117 
potential items were assessed for 
their ability to be translated, their 
relevance, potential to discriminate 
IBS severities, importance, and 
ability to detect change over time.  
 
 
The initial 117 items were reduced to 41 items. These 41 items were further reduced to 34 following 
cognitive debriefing reports, patient ranked importance and investigator opinion due to redundancy, 
ceiling effect, and low item-scale correlation.  
 
Predicted hypothesis correlations between the IBS-QOL overall and SF-36 were met except for the 
scales for vitality (weaker than predicted) and mental health (stronger than predicted). Of the seven 
scales of the PGWB only the scales total score and health worry concern were correlated as predicted 
(stronger). Construct validity predictions comparing the SCL90-R and the IBS-QOL were met for 7 of the 
10 scales. It was hypothesized that the scales global score, somatization, and obsessive 
compulsiveness would weakly correlate, however, these scales were strongly correlated.  
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Table 2.1 continued 
Questionnaire  Symptoms  Method of validation Results of validation 
Irritable Bowel 
Syndrome 
Quality of Life 




6. Social reaction  
(4 items) 






Validity was determined using the 
following questionnaires: the SF-
36, the PGWB, and the symptom 
checklist (SCL90-R). Pearson’s 
correlation coefficients were 
calculated to determine the 
strength of association between 
these questionnaires and the IBS-
QOL.  This measured the 
correlations (criterion validity) and 
a priori hypotheses (construct 
validity) about the strengths 
(convergent validity) or 
weaknesses (discriminant validity) 
of association between the 
questionnaires.  
Known groups discriminant validity 
was assessed examining symptom 
frequency and bothersomeness 
(mild, moderate and high) against 
the IBS-QOL scales and the SF-36 
scales. Self-rating of severity and 
the number of IBS episodes in the 
past week were also assessed. 
 
 
Predicted vs actual correlations between the IBS-QOL and SF-36 
 IBS-QOL (overall scale) 
 Predicted Actual Confirmed 
SF-36    
Physical function Weaker 0.36 Yes 
Role physical  Stronger 0.40 Yes 
Bodily pain Stronger 0.47 Yes 
General health Weaker 0.37 Yes 
Mental health Weaker 0.41 No 
Role emotional Weaker 0.31 Yes 
Vitality  Stronger 0.30 No 
Social function Stronger 0.44 Yes 
  *Weaker correlation: <0.40; stronger correlation: >0.40. 
Lower symptom frequency and symptom bothersomeness were associated with higher quality of life 
scores for patients completing the IBS-QOL and SF-36. As patient reported severity worsened, so too 
did the patient IBS-QOL total score.  
 
 Summary of comparisons of symptom frequency and bothersomeness reports and HR-QOL measures 
 Symptom Frequency Index Symptom Bothersome Index 
 Mild Moderate High Mild Moderate High 
IBS-QOL       
Overall  69.7 64.6 55.0* 72.2 64.8 53.8* 








58.7 54.1 42.9* 60.1 52.8 44.2* 
Higher quality of life 






significant at the 
p<0.0001 level.  
 
 
   * p<0.0001 
Values are means, and statistical tests are analysis of variance. Higher values indicate better HR-QOL. 
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symptoms while insoluble fibre supplements (bran) have been shown to worsen IBS 
symptoms (15, 17). Fibre, both soluble and insoluble, is found in a typical diet in plant-
based foods; there is insufficient evidence to suggest patients with IBS have different 
fibre requirements than the general population (12).   
2.3.2 Gluten   
A gluten-free diet may improve gastrointestinal symptoms in IBS patients. Gluten is a 
dietary protein found in wheat, rye, barley and oats and a dietary restriction has been 
shown to reduce the symptoms of abdominal pain, tiredness, stool consistency, stool 
frequency and bloating (18-20). It is important to note that while these studies excluded 
people with coeliac disease, they did not control for dietary factors such as FODMAPs. A 
gluten-free diet also reduces the intake of the FODMAPs, therefore the reduction of 
FODMAPs may, in fact, be the cause for the improvement in IBS symptoms in those who 
do not have coeliac disease (21, 68, 69). The data concerning the efficacy of gluten as a 
treatment option for IBS are conflicting and more research is required (12, 69).   
2.3.3 FODMAPs   
 
Poorly absorbed, rapidly fermentable short-chain carbohydrates and polyols can trigger 
gastrointestinal symptoms due to their osmotically active and highly fermentable nature 
(22). These carbohydrates and polyols are poorly absorbed in the small intestine and 
subsequently, due to their highly osmotic effect, increase intestinal water content and 
then pass unabsorbed into the large intestine where they induce gas production due to 
their fermentation by colonic bacteria (22). The resultant luminal distension can 
exacerbate the abdominal symptoms of bloating and abdominal pain common in IBS 
(33). Collectively these carbohydrates and polyols are referred to as FODMAPs and 
comprise fructans, galacto-oligosaccharides (GOS), lactose, fructose (in excess of 
glucose), and polyols.  
 
FODMAPs are poorly absorbed to some degree in all individuals (24). The malabsorption 
of FODMAPs is specific to a given individual, therefore not all IBS patients will 
experience gastrointestinal symptoms at the same severity, if at all, following the 
consumption of FODMAPs (24). Dietary management of FODMAP consumption can 
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alleviate the gastrointestinal symptoms of abdominal pain, bloating, and diarrhoea in IBS 
(12, 23, 70, 71).  
2.4 Dietary assessment methods 
The food consumption of individuals can be measured by quantitative (measuring actual 
intake) or retrospective (estimating usual intake) methods. Quantitative methods to 
measure food consumption include the 24-hour recall method, estimated food records, 
and weighed food records (25). These quantitative methods measure the quantity of an 
individual’s food consumption over a 1-day period. In order to measure an individual’s 
usual food consumption, measurement of multiple days of food records or recalls is 
necessary (25). Retrospective methods to measure food consumption consist of the 
dietary history and the food frequency questionnaire (25). These methods enable the 
collection of data about an individual’s pattern of food consumption during a longer 
period of time (25).  
2.4.1 Methods for measuring food consumption of individuals 
 
The 24-hour recall method requires an individual to recall their food intake during the 
previous 24-hours to a trained interviewer (25, 72). Repeated 24-hour recalls can 
determine an individual’s usual food consumption, accounting for day-to-day and 
seasonal variation (25, 72).  
Estimated food records require an individual to measure and record all food and 
beverages consumed using household measures at the time of consumption, for a 
specified time period (25, 72). Individuals must record detailed descriptions of all 
products consumed, including brand names of products as well as the preparation and 
cooking methods (25, 72).   
Weighed food records require an individual to weigh and record all food and beverages 
consumed at the time of consumption, for a specified time period (25, 72). Individuals 
must record detailed descriptions of all products consumed, including brand names of 
products as well as the preparation and cooking methods (25, 72).   
The dietary history method is used by trained interviewers or computerized versions to 
estimate an individual’s food and beverage consumption over a specified period of time – 
often a month (25, 72). Overall eating patterns and the frequency of consumption, and 
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portion sizes, of specific foods, are assessed (25). Dietary histories traditionally 
incorporated an estimated three-day food record, these are now often omitted in favour of 
a 24-hour recall following which a trained interviewer will gather detailed information 
about usual foods consumed and the frequency of consumption (25, 72).  
The food frequency questionnaire method of assessing an individual’s food consumption 
requires the individual to complete a self-administered questionnaire, or partake in an 
interview to complete the questionnaire (25, 72). The food frequency questionnaire 
provides information about an individual’s usual food consumption patterns over a 
specified period of time, determining the frequency with which certain food items and 
food groups are consumed (25, 72).  
2.4.2 Benefits and limitations of dietary assessment methods 
 
Multiple day food records, weighed or estimated, are the most reliable method to 
determine the dietary intake of individuals because the information is recoded 
concurrently to consumption, eliminating the need to recall, and potentially forget, food 
consumed at a later point. Estimation of portion sizes leads to less respondent burden, 
while weighed food records will reduce the chance of random error (72). However, 
multiple day food records do have a high respondent burden (72). To account for day-to-
day variation and to assess the habitual intake of an individual, multiple non-consecutive 
days should be recorded (25).   
 
Food frequency questionnaires have a much lower respondent burden, provide an 
estimate of usual consumption patterns, and are retrospectively completed. This means 
participants must recall what they typically consume, providing an opportunity for error 
(72). Long term recall can differ significantly from short-term recall (73). 24-hour recalls 
are also collected retrospectively, requiring participants to remember the food they have 
consumed the day prior. This recall period is less than that of a food frequency 
questionnaire, and a trained interviewer completes the recall, leaving little chance for 
items to be forgotten. However, if only one 24-hour recall is completed, there can be 
substantial error due to daily variation as individuals do not consume the same foods 
every day (72). Underreporting is a source of error arising in all methods of dietary 
assessment, and is most a problem when assessing total energy intake (72). To gather 
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information about how food consumption directly relates to gastrointestinal symptoms, 
the multiple-day food records will provide the most accurate and informative record of 
food consumption.  
2.4.3 Food and symptom diaries 
Food and symptom diaries have been utilised for decades, primarily in the discovery of 
food allergies, enabling practitioners to determine the food cause of a symptom. Food and 
symptom diaries incorporate multiple day food records, weighed or estimated, and record 
relevant symptoms (72). Somewhat surprisingly due to the extensively described 
influence that food has on gastrointestinal symptoms in IBS, only a few food and 
symptom diaries are mentioned in the literature. Daily symptom reporting of 
gastrointestinal symptoms for IBS-D and IBS-C in diaries, event logs, and phone 
interviews have been validated and shown to be more accurate than retrospective 
symptom reporting (6, 74-77).  One food and symptom journal for smartphones has been 
created in America for IBS (78), and Monash University of Australia have created a low  
FODMAP smartphone application with a diary for daily symptoms and food intake (79), 
neither of which have currently been validated (see Table 2.2 for further details). These 
food and symptom diaries may not accurately report the information they aim to record.  
While there is also a breadth of diaries in women’s magazines, smartphone applications, 
and self-help websites, the methodology of collecting this information is not validated. 
There is a need for a NZ specific food and symptom diary for IBS. Food composition 
databases are country specific, compiling common foods eaten in the country and foods 
unique to that country’s culture (80). Therefore, relying on data from American or 
Australian diaries may not provide accurate information on foods and nutrients consumed 
in NZ. While the Monash application does have some NZ specific data, to determine 
which foods or nutrients are causing gastrointestinal symptoms it is necessary to have a 
NZ food composition database for analysis. Although there are food and symptom diaries 
for IBS, there are none that are validated. Therefore, validating a diary that contains a 
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Table 2.2 Description of food and symptom diaries for irritable bowel syndrome 
2.5 Summary and aim   
Irritable bowel syndrome is characterised by symptoms of abdominal pain, bloating, 
changes in bowel habits, and distension. There have been many validated questionnaires 
to assess these symptoms retrospectively. However, patients report these symptoms 
fluctuate throughout the day and are influenced by food intake.  Surprisingly, there is no 
validated instrument to concurrently record food and gastrointestinal symptoms for IBS 
patients. Due to the causative effect that certain foods have on subsequent gastrointestinal 
symptoms, it is necessary to determine which foods influence these symptoms and the 
mechanisms behind these effects to treat the symptoms of IBS. The aim of this research is 
to investigate the associations between the consumption of fibre, gluten, and high 
FODMAP foods and the subsequent gastrointestinal symptoms in adults with IBS to 
increase the knowledge and options for the dietary management of IBS, leading to 
improvements in quality of life for IBS patients. To achieve this, a real-time food and 
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All symptoms are 
recorded in the diary 
at the end of the day. 
Meals and snacks 
are added into the 
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add your own 
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No 
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3. Objective Statement  
As described above, IBS patients report food as the most common trigger for their 
gastrointestinal symptoms. One method to determine which food items may be 
attributable to causing or worsening gastrointestinal symptoms is a food and symptom 
diary. Incorporating a real-time gastrointestinal symptom scale into the diary enables 
accurate real-time information about symptom duration and severity to be recorded. 
This will enable the investigation into which foods and nutrients may have a real-time 
influence on gastrointestinal symptoms, increasing the knowledge of dietary 
management in the treatment of IBS symptoms. 
 
Research Aim: The purpose of this pilot study was to examine the relationship 
between the consumption of fibre, gluten, and FODMAPs and gastrointestinal 
symptoms in adult IBS participants. The research objectives are to: 
- Pilot test the real-time food and symptom diary in adult IBS participants. 
- Assess the relative validity of the real-time gastrointestinal symptom scales in 
the food and symptom diary against selected legacy instruments. 
- Assess the consumption of fibre, gluten, and FODMAPs in a sample of adult 
IBS participants. 
- Investigate the relationship between food intake, specifically fibre, gluten, and 
FODMAPs, and gastrointestinal symptoms.  
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4. Methods  
 
4.1 Study design 
The aims of this prospective observational study were to - 
1.  determine the predictive validity of the food and symptom diary by 
investigating the relationship between the consumption of food and subsequent 
gastrointestinal symptoms (occurrence and severity), and; 
2.  test the relative validity of a real-time food and symptom diary which records 
the consumption of food and gastrointestinal symptoms on a regular basis 
throughout the day, over three days. 
This thesis focuses on investigating the relationship between the intake of selected 
foods and nutrients (specifically fibre, gluten and FODMAPs) and subsequent 
gastrointestinal symptoms, and will also discuss the validity of the real-time 
gastrointestinal symptom rating within the diary.  
 
Ethical approval was obtained from the University of Otago Human Ethics Committee 
(Health) (Reference H16/094) (Appendix A)), and Māori consultation was carried out 
by Te Komiti Whakarite Research Consultation Committee (Appendix B).   
 
4.1.1 Development of the food and symptom diary 
The diary was informally pre-tested by 10 IBS patients and 5 research staff with 
extensive experience in the development of similar methodology who provided 
iterative verbal feedback on the questionnaire and diary. As the wording of the 
gastrointestinal symptom questions included in the diary did not change, just the 
timescale that these cover, the understanding of the questions remained unchanged. 
The real-time gastrointestinal symptom scales were embedded within the body of the 
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diary (see Appendix E for further details).  The food diary component of the food and 
symptom diary is a standard format used in research. This study is pilot testing the 
food and real-time gastrointestinal symptom diary to be used in the COMFORT 
cohort to remove any flaws in the design. All participants completed a questionnaire 
about the diary following completion of the study to provide feedback on the diary 
design which is described in section 4.3.4. 
 
4.2 Participants 
A convenience sample of 51 participants were recruited from the cities of Dunedin 
and Christchurch via medical centres, gastroenterology clinics, university campuses, 
and local shopping areas between September 2016 and April 2017. Participants aged 
between 18-65 who satisfied the Rome IV criteria for the diagnosis of IBS were 
considered for inclusion in the study. The Rome IV criteria are detailed in section 
4.3.2. Those with organic gastrointestinal disease or a significant active co-morbidity 
were excluded. All participants provided signed informed consent.  
 
This is an observational study with no previous data concerning the validation of a 
time specific food and symptom diary in IBS participants available, therefore a 
sample of 50 participants was considered reasonable. 
 
4.3  Study procedures 
An outline of the study procedures is shown below (Figure 4.1). All prospective 
participants gave signed consent and completed a demographics form and the Rome 
IV diagnostic questionnaire for adults, irritable bowel syndrome module. Those 
eligible for the study were given four questionnaires (one about the diary and the 
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following legacy instruments: the GSRS, the IBS-QOL, and the PROMIS GI scales) 
and the food and symptom diary to complete. Dunedin participants received these in 
person, Christchurch participants had the documents sent by mail. Participants were 
given detailed guidance on how to complete the food and symptom diary. They were 
asked to fill in the diary on three non-consecutive days including one weekend day, 
recording food intake and gastrointestinal symptoms as they occur, and then following 
completion of the diary to fill in the four questionnaires and return them all by mail or 
in person. Participants received a $20 voucher as reimbursement for any expenses or 
the cost of participating in the study, following completion of the study. 
 
 
Figure 4.1 Study procedures 
4.3.1 Demographic questionnaire 
Participants initially completed a demographic questionnaire (Appendix C), 
containing information on sex, age, ethnicity, and questions about the participant’s 
medical history to assess eligibility for the study.  
Participant Screening: 
Participant consent gained, demographic questionnaire completed, and ROME IV 
questionnaire completed  
If study criteria met, participant receives diary and questionnaires  
Food and Symptom Diary: 
Participants received instructions on how to fill in the diary, and completed this over 
three non-consecutive days during one week period including one weekend day 
Questionnaires: 
After the final day of diary recording, participants were instructed to complete the 
legacy instruments (GSRS, IBS-QOL, PROMIS GI Scales) and the questionnaire 
about the diary 
Participant returns diary and questionnaires in person or by mail 
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4.3.2 Rome IV diagnostic questionnaire for adults, irritable bowel syndrome 
module 
Participants completed the Rome IV diagnostic questionnaire for adults, irritable 
bowel syndrome module to assess eligibility for the study. This also categorised 
participants according to IBS subtype, aksing about the abnormal stools that 
participants had experienced over the past 3 months, using the bristol stool chart. 
Participants were classified as IBS-D (IBS with diarrhoea) if usual abnormal bowel 
motions were type 6-7, IBS-C (IBS with constipation) if type 1-2, IBS-M (IBS with 
mixed bowel habits) if type 1,2, and type 6-7 were experienced, and IBS-U (IBS 
unclassified) if the participant rarely had abnormal bowel motions.   
The Rome IV diagnostic criteria participants must have experienced (for the past 3 
months with symptom onset at least 6 months before diagnosis) to be diagnosed with 
IBS are listed below.  
 
Recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, 
associated with two or more of the following criteria: 
1. Related to defecation 
2. Associate with a change in frequency of stool 
3. Associated with a change in form (appearance) of stool (1) 
 
4.3.3 The food and symptom diary 
The three-day food and symptom diary (Appendix E) includes a food diary section, 
24-hour scales to record symptoms, and information about bowel motions. 
Participants recorded all food and beverages consumed at the time of consumption, 
    23 
where they were and who they were with at the time of consumption, descriptive 
information about the food or beverage consumed, how the food or beverage was 
prepared and/or cooked, and the amount of this food or beverage consumed. The diary 
also had a recipe section for participants to record the ingredients of a prepared recipe 
and how much of the recipe they consumed. To facilitate accurate recording, the diary 
contained written instructions with examples of how to record food intake.   
 
The 24-hour scales were used to record the gastrointestinal symptoms of abdominal 
pain, abdominal swelling/distension, abdominal fullness, and abdominal bloating. For 
each symptom, participants recorded the time at which each symptom was 
experienced, the duration of this symptom on a 24-hour scale, and the severity of the 
symptom. Symptom severity ranged from 1 ‘not bad at all’ to 5 ‘very bad’. If a 
participant did not experience one of the symptoms on one of the days, they ticked a 
box indicating this.  
 
Bowel motions were also recorded on a 24-hour scale. Participants then recorded the 
following information for each bowel motion: Bristol stool type, if there was any 
straining to pass the bowel motion, if abdominal pain was felt before the bowel 
motion, how much urgency was experienced, and whether the abdominal pain was 
relieved or worsened following the bowel motion.  
 
4.3.4 Questionnaire about the food and symptom diary 
The questionnaire about the food and symptom diary (Appendix F) asked the 
participants to report how accurate they were reporting their gastrointestinal 
symptoms and food and beverage intake, whether they understood how to complete 
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the diary, and whether the diary was an inconvenience to them, with space to further 
explain if necessary. There was a section for participant to write any suggested 
improvements to the diary.  
 
4.3.5 The legacy instruments 
The questionnaires used in this study were the following legacy instruments: the 
GSRS (Appendix G), the IBS-QOL (Appendix H), and the PROMIS GI scales 
(Appendix I). These are discussed in section 2.2.2 and described in Table 2.1. 
Correlations between the legacy instruments and the food and symptom diary real-
time gastrointestinal symptoms were assessed.  
 
Correlation coefficients measure the degree to which items are associated but not how 
well the items agree. Whilst there should be some correlation between the long term 
symptoms reported in the legacy instruments and the real-time gastrointestinal 
symptoms reported in the food and symptom diary as they are measuring the same 
variable (gastrointestinal symptoms of the same participants during the same week), it 
is anticipated that the correlation between these two constructs will be modest because 
long term recall can differ significantly from short term recall and symptoms can 
fluctuate throughout the day. Spearman’s correlation coefficients were used to 
measure the strength of the association.  
 
It is outside the scope of this thesis to evaluate the relationship between diet and the 
participant’s quality of life as determined by their IBS-QOL score, or between diet 
and the patient-reported outcomes measured in the GSRS and PROMIS GI scales. 
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4.4  Data entry 
4.4.1 Demographic questionnaire data entry 
Data from the demographic questionnaire were entered into a Microsoft Excel version 
15.32 (Microsoft Corporation, Redmond, Washington, U.S.A) spreadsheet, along with 
the participant’s IBS subtype as determined by the Rome IV diagnostic questionnaire 
for adults, irritable bowel syndrome module.  
 
4.4.2 Food diary data entry 
The food diary collected three days of information about each participant’s food and 
beverage intake. This information was entered in the dietary assessment software Kai-
culator (version 1.15k) developed in the Department of Human Nutrition at the 
University of Otago. The candidate entered all 153 days of food diary data, limiting 
interpersonal variation in data entry. The Kai-culator food and nutrient composition 
database contains the NZ Institute of Plant and Food Research FOOD files (2010), 
recipes developed for the 2008/09 NZ Adult Nutrition Survey, and newly developed 
recipes that consider moisture and nutrient changes that occur during the cooking of 
recipe foods.  
 
The Kai-culator diary entries were screened for data anomalies by an experienced 
dietitian to check the accuracy of data entry, and any errors were corrected. 
 
The food items which participants ate were exported from Kai-culator into a 
Microsoft Excel spreadsheet, detailing the name and amount of the food eaten and the 
nutrient content.  
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4.4.3 Allocation of fibre, gluten, and FODMAP food groups 
The fibre content of the foods was available within Kai-culator, therefore, fibre intake 
was described in tertiles of high, medium, or low fibre intake based on mean daily 
consumption.   
 
Kaiculator does not contain gluten, therefore all food items were individually 
recorded as gluten free or gluten containing according to the item’s individual 
ingredients. Foods containing wheat, rye, barley or oats and any of their derivatives 
were classified as gluten containing as recommended by the New Zealand Coeliac 
Society and required by the Australia New Zealand Food Standards Code (81). The 
gluten containing foods were further classified by the number of servings of the food 
that were consumed, according to the Ministry of Health ‘Eating and activity 
guidelines for New Zealand adults’ advice for serving sizes (82).  Participants were 
allocated into tertiles of high, medium, or low gluten intake based on mean daily 
consumption of gluten containing food servings.  
 
The FODMAP content of the food items is also not included in Kai-culator. The foods 
were individually allocated as having a low/no, moderate, or high FODMAP content 
according to the Monash University Low FODMAP Diet Application (79). The 
application contains information about the FODMAP content of food items when 
consumed in varying amounts. Food items that were not recorded in the application, 
such as some baked goods, sauces and chutneys, processed meats, pizza, and some 
breakfast cereals were allocated according to the item’s individual ingredients and 
compared to the FODMAP content of similar items. Meal items such as chilli con 
carne and stir-fried dishes were also allocated by the candidate according to the 
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FODMAP content of the individual meal ingredients and the amount of the meal 
consumed. The participants were allocated into tertiles of high, medium, or low/no 
FODMAP intake based on mean daily consumption of FODMAP containing foods. 
One moderate FODMAP containing food was assumed to contain half of the 
FODMAPs that a high FODMAP food contained.  While it is outside the scope of this 
thesis to look at the cumulative effect of FODMAP consumption on gastrointestinal 
symptoms, this will be investigated by the candidate in future research.  
 
All gluten and FODMAP food item allocations by the candidate were checked by an 
experienced nutritionist and dietitian.  
 
4.4.4 Gastrointestinal symptom diary data entry 
Data from the gastrointestinal symptoms recorded in the food and symptom diary 
were entered in a Microsoft Excel spreadsheet, recording symptoms occurrence over a 
24 hour window in 30 minute sections, and reporting the severity of these symptoms.  
 
4.4.5 Questionnaire data entry 
The GSRS, IBS-QOL, and the PROMIS GI scales questionnaire responses were 
entered in a Microsoft Excel spreadsheet, in accordance with the scoring instructions 
for each respective questionnaire. The responses for the questionnaire about the food 
and symptom diary was also entered in a Microsoft Excel spreadsheet.  
 
4.5  Statistical analysis 
The descriptive statistics for the demographic data were performed by the candidate 
using Microsoft Excel. The candidate also carried out basic statistical analyses of the 
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fibre, gluten, and FODMAP data according to IBS subtype. The participant’s 
gastrointestinal symptom severity and duration were analysed as a mean across each 
of the 24-hour periods and aggregated to provide a mean daily duration and severity 
across the three days of diary recording. The participant’s food intake was also 
analysed as a mean across each of the 24-hour periods and aggregated to provide a 
mean daily intake over the three days of diary recording. Statistical analysis of the 
real-time gastrointestinal symptoms, the participant’s food and beverage intake and 
the real-time gastrointestinal symptom scales correlations with the legacy documents 
were performed by a biostatistician using Stata Statistical Software version 14.2 
(StataCorp, College Station, Texas, U.S.A). In this study, predictive validity refers to 
the to the broader sense of how well the results of the symptom scales reflect what 
would be expected by the food choices made by the participants. Trends of median 
daily gastrointestinal symptoms across tertiles of mean daily fibre, gluten, and 
FODMAP consumption were determined using median regression, investigating the 
predictive validity of the diary. The association of mean daily fibre intake and fibre 
intake tertiles with IBS subtype was assessed using a one-way ANOVA and a Fisher’s 
exact test, respectively. Significance levels for all the tests were set at p<0.05. 
 
4.5.1 Relative validity 
Correlations between the real-time gastrointestinal symptom scales and the legacy 
instruments were examined using Spearman correlation coefficients. Based on expert 
recommendations and previous research, acceptable correlation coefficients for 
symptom scales and legacy instruments can be classified as weak (<0.30), moderate 
(0.30-0.60) and strong (>0.60) (4, 5, 45, 48).   
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The construct validity of the real-time gastrointestinal symptom scales against legacy 
instruments was tested. One method of establishing the validity of a patient-reported 
outcome (in this case, the real-time gastrointestinal symptom scales) is to measure its 
relationship with other established legacy instruments. Comparing logically related 
measures, such as the real-time gastrointestinal symptom abdominal pain and the 
GSRS subscale abdominal pain, to see if they are correlated more strongly 
(convergent) or weakly (discriminant) enables the establishment of construct validity 
if a priori expectations are met.  Thus, we hypothesised a priori that the real-time 
gastrointestinal symptom scales would modestly and significantly correlate with 
logically selected subscales and questions from the legacy instruments listed in 
section 4.4. There were no scales in the legacy instruments that were logically related 
to the real-time symptom of abdominal fullness, thus this symptom was not analysed 
for correlation. The legacy instruments also did not have questions logically related to 
each of the real-time symptoms recorded for each bowel motion, only their scales of 
diarrhoea, constipation, and questions related to the frequency of bowel motions were 
analysed for correlation. The overall score of the IBS-QOL was analysed for 
correlation with the real-time gastrointestinal symptom scales. 
 
The gastrointestinal symptom abdominal pain is logically related to the following 
legacy instrument scales and individual questions: 
- GSRS scale of abdominal pain 
- GSRS question 1: Have you been bothered by pain or discomfort in your 
abdomen or the pit of your stomach during the past week? 
- PROMIS GI scale of belly pain 
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- PROMIS GI scales question 1: In the past 7 days, how often did you have 
belly pain? 
- PROMIS GI scales question 2: In the past 7 days, at its worst, how would you 
rate your belly pain? 
 
The gastrointestinal symptom abdominal swelling/distension is logically related to the 
following legacy instrument scales and individual questions: 
- GSRS scale of indigestion 
- GSRS question 7: Has your stomach felt bloated during the past week? 
(Feeling bloated refers to the swelling often associated with a sensation of 
gasses in the stomach.) 
- PROMIS GI scale of gas/bloating 
- PROMIS GI scales question 33: In the past 7 days, how much swelling did 
you have in your belly? 
- PROMIS GI scales question 34: In the past 7 days, how bad did the swelling 
in your belly get? 
 
The gastrointestinal symptom abdominal bloating is logically related to the following 
legacy instrument scales and individual questions: 
- GSRS scale of indigestion 
- GSRS question 7: Has your stomach felt bloated during the past week? 
(Feeling bloated refers to the swelling often associated with a sensation of 
gasses in the stomach.) 
- PROMIS GI scale of gas/bloating 
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- PROMIS GI scales question 37: In the past 7 days, how often did you feel 
bloated? 
- PROMIS GI scales question 38: In the past 7 days, in general, how severe was 
your bloating? 
- PROMIS GI scales question 39: In the past 7 days, at its worst, how severe 
was your bloating? 
- PROMIS GI scales question 40: In the past 7 days, in general, how severe did 
your bloating feel? 
 
The gastrointestinal symptom bowel motions are logically related to the following 
legacy instrument scales and individual questions: 
- GSRS scale of diarrhoea 
- GSRS question 11: Have you been bothered by diarrhoea during the past 
week? (Diarrhoea refers to a too frequent emptying of the bowels.) 
- GSRS question 12: Have you been bothered by loose stools during the past 
week? (If your stools (motions) have been alternately hard and loose, this 
question only refers to the extent you have been bothered by the stools being 
loose.) 
- GSRS scale of constipation 
- GSRS question 10: Have you been bothered by constipation during the past 
week? (Constipation refers to a reduced ability to empty the bowels.) 
- GSRS question 13: Have you been bothered by hard stools during the past 
week? (If your stools (motions) have been alternately hard and loose, this 
question only refers to the extent you have been bothered by the stools being 
hard.) 
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- PROMIS GI scale diarrhea 
- PROMIS GI scale question 16: In the past 7 days, how many days did you 
have loose or watery stools? 
- PROMIS GI scale constipation 
- PROMIS GI scale question 7: In the past 7 days, how often did you pass hard 
or lumpy stools?  
- PROMIS GI scale question 8: In the past 7 days, how much did hard or lumpy 
stools bother you? 
 
Spearman’s correlation coefficients between the real-time gastrointestinal symptom 
scales and each of the theoretically related selected subscales and questions from the 
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5. Results  
 
5.1 Sample characteristics 
Eighty-seven participants enrolled in the study and signed a written consent form. 22 
participants did not meet the Rome IV criteria for the diagnosis of IBS and were thus 
excluded from the study. Fourteen participants did not reply or return the study 
documents. This gave a sample of 51 IBS participants (78.5% of the 65 eligible 
participants) satisfactorily completing the study.  
 
Table 5.1 displays the demographic characteristics of the 51 study participants. Most 
the participants were female (96.1%), 11.8% identified as Maori, and the majority of 
participants had diarrhoea predominant IBS according to the Rome IV diagnostic 
criteria. Both male participants experienced IBS-D.  
Table 5.1 Demographic characteristics of study participants1 
 All participants (n=51) 
Sex  
    Female 49 (96.1) 
    Male 2 (3.9) 
Age (mean(SD))  29.1 (11.8) 
Ethnicity   
   New Zealand European 37 (72.6) 
   Maori 2 6 (11.8) 
   Other 8 (15.7) 
Irritable bowel syndrome subtype  
    Irritable bowel syndrome with constipation (IBS-C) 11 (21.6) 
    Irritable bowel syndrome with diarrhoea (IBS-D) 22 (43.1) 
    Irritable bowel syndrome with mixed bowel habits (IBS-M) 18 (35.3) 
    Irritable bowel syndrome unclassified (IBS-U) 0 (0) 
1 All data expressed as n (%) unless otherwise specified. 
2 Participants who identified as Maori and another ethnicity were counted as Maori.  
 
5.2 The real-time gastrointestinal symptoms 
The participants experienced the real-time gastrointestinal symptoms daily for a 
median time of 50-100 minutes (abdominal fullness - abdominal pain) at a median 
severity of ‘not bad at all’ or ‘a little bad’. Abdominal pain was the most severe 
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symptom experienced by participants, and was felt for the longest duration of time 
(Table 5.2).   
Table 5.2 Median length of time and severity of the real-time gastrointestinal 
symptoms experienced daily by participants1 
 Median length of time per day 
the symptom was experienced 
(minutes) 
Median daily severity of 
symptom experienced2 
Abdominal Pain 100 (50,190) 2.4 (1.7, 2.8) 
Abdominal Swelling/Distension 60 (0,140) 1.3 (0.0, 1.3) 
Abdominal Fullness 50 (10, 150) 1.3 (0.7, 2.7) 
Abdominal Bloating 80 (20,200) 2 (0.7,2.7) 
Bowel Motions3                  1.3 (1.0,2.3) 
1 All data expressed as median (25th percentile, 75th percentile). 
2 Severity; 1 ‘not bad at all’, 2 ‘a little bad’, 3 ‘somewhat bad’, 4 ‘quite bad’, 5 ‘very bad’. 
3 Number of bowel motions experienced.   
 
5.3 Relative validity of the real-time gastrointestinal symptom scales 
Construct validity of the real-time gastrointestinal symptoms was evaluated by 
examining the correlations between the real-time gastrointestinal symptom scales and 
the GSRS, PROMIS GI scales and the IBS-QOL. No exceptionally strong correlations 
were observed (see Table 5.3 for further details). The correlations (0.280-0.654) 
between the severity of the real-time gastrointestinal symptom scales, the GSRS, and 
PROMIS GI scales were all statistically significant. All of the correlations between 
the selected PROMIS GI scales and questions were moderately correlated with the 
real-time gastrointestinal symptom scales and statistically significant (p<0.05), with 
the exception of the subscale constipation and related questions. The strongest 
associations were with abdominal bloating (0.654).  The length of time symptoms 
were experienced yielded correlations below 0.3 for some of the GSRS subscales (the 
indigestion subscale had a correlation of 0.199 with the diary symptom abdominal 
bloating), but not for the specific GSRS questions which directly related to the real-
time gastrointestinal symptoms in the diary (the question relating to bloating had a 
correlation of 0.315 with the diary symptom abdominal bloating).  
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Table 5.3 Correlation of the real-time gastrointestinal symptom scales and selected 
subscales and questions from the GSRS, the PROMIS GI Scales, and the IBS-QOL 
legacy instruments 
 Abdominal Pain Abdominal Swelling/ 
Distension 














GSRS Scales1        
Abdominal pain 0.221 0.280*      
   GSRS Q1 
   Abdo- pain 
0.253 0.295*      
Indigestion   0.167 0.288* 0.199 0.382*  
   GSRS Q7 
   Bloating  
  0.312* 0.372* 0.315* 0.464*  
Diarrhoea       0.307* 
   GSRS Q11 
   Diarrhoea 
      0.267* 
   GSRS Q12 
   Loose stools 
      0.358* 
Constipation       -0.118 
   GSRS Q10 
   Constipation 
      -0.179 
   GSRS Q13 
   Hard stools 
      -0.207 
PROMIS GI 
Scales1 
       
Abdominal pain 0.359* 0.424*      
   PROMIS Q1 
   Frequency 
0.470* 0.398*      
   PROMIS Q2 
   Severity 
 0.426*      
Gas/bloating   0.487* 0.577* 0.394* 0.528*  
   PROMIS Q33 
   Swelling 
  0.499* 0.565*    
   PROMIS Q34 
   Swell severity 
  0.439* 0.456*    
   PROMIS Q37 
   Bloating 
    0.438* 0.654*  
   PROMIS Q38 
   Bloating often 
    0.356* 0.535*  
   PROMIS Q39 
   Bloat severity 
    0.382* 0.476*  
   PROMIS Q40 
   Bloating max 
    0.379* 0.424*  
Diarrhea       0.308* 
   PROMIS Q16 
   Frequency 
      0.408* 
Constipation        -0.054 
   PROMIS Q7 
   Frequency 
      -0.023 
   PROMIS Q8 
   Severity 
      -0.060 
IBS-QOL 
Score1 
       
   Overall  0.23 0.16 0.39* 0.33* 0.23 0.06 0.06 
*P-value of <0.05 is considered statistically significant. 
1 The legacy instruments are detailed in Appendix G, H, and I.   
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The mean IBS-QOL overall score of 39.0(±17.0) was found to moderately correlate 
with the real-time gastrointestinal symptom of abdominal swelling/distension 
(p<0.05). 
5.4 Analysis of the gastrointestinal symptoms according to food intake 
Comparison of the participants’ gastrointestinal symptoms according to the 
participants’ intake of fibre, gluten, and FODMAPs are presented in Table 5.4.  
Mean daily fibre intake in each of the tertiles is 16.0g for the low tertile, 23.1g for the 
middle tertile, and 31.7g for the high tertile. Mean daily gluten servings consumed in 
each of the gluten tertiles is 1.7 serves of gluten containing foods for the low tertile, 
3.9 serves of gluten containing foods for the middle tertile, and 5.9 serves of gluten 
containing foods for the high tertile. The mean daily intake of high FODMAP foods in 
each tertile is 3.7 high FODMAP foods for the low tertile, 5.7 high FODMAP foods 
for the middle tertile, and 8.4 high FODMAP foods for the high tertile.  
 
The were no significant trends for real-time gastrointestinal symptoms across the 
tertiles of high, medium, and low intakes of fibre, gluten, and FODMAPs, with the 
exception of abdominal bloating and FODMAPs consumption, and abdominal pain 
and straining prior to bowel motions according to fibre consumption. A lower 
consumption of FODMAPs was significantly related to a lower severity of abdominal 
bloating (severity of 0.7 in the low FODMAP tertile, 1.7 in the middle tertile, and 2.3 
for the high tertile). Fibre intake was inversely associated with straining and 
abdominal pain prior to bowel motions, consuming less fibre was associated with an 
increase in abdominal pain prior to a bowel motion (severity of 2.7 in the low fibre 
tertile, 2.1 in the middle, and 1.7 in the low tertile of intake) and more straining to 
have the bowel motion (severity of 2.7 in the low fibre tertile, 2.1 in the middle, and  
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Table 5.4 Median daily gastrointestinal symptoms experienced by participants 
according to mean daily intake of fibre, gluten, and FODMAPs 1  
 Fibre Gluten FODMAPs 
High Middle Low High Middle Low High Middle Low 
Abdominal Pain    
   Length of time      

























































   
   Length of time 
   (minutes) 
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140) 















































Abdominal Fullness     
   Length of time 























































Abdominal Bloating    
   Length of time 






















































Bowel Motions    
   Daily motions3  1.3 
(1, 
1.7) 
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1 All data expressed as median (25th percentile, 75th percentile). 
2 Severity; 1 ‘not bad at all’, 2 ‘a little bad’, 3 ‘somewhat bad’, 4 ‘quite bad’, 5 ‘very bad’. 
3 Number of bowel motions per day.  
4 Straining; 1 ‘not at all’, 2 ‘slightly strain’, 3 ‘moderately strain’, 4 ‘significantly strain’, 5 
‘unable to empty bowel’ 
5 Abdominal pain; 0 ‘no abdominal pain’, 1 ‘not bad at all’, 2 ‘a little bad’, 3 ‘somewhat bad’, 4 
‘quite bad’, 5 ‘very bad’. 
6 Urgency; 1 ‘not at all’, 2 ‘a little urgency’, 3 ‘I have to hurry’, 4 ‘I have to go immediately’, 5 ‘I 
am incontinent (unable to control the urge and had an accident)’. 
* A p-value of <0.05 is considered statistically significant, looking at the trend across tertiles 
using median regression.  
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2.0 in the low tertile of intake). The relationships for these associations were both 
statistically significant (p<0.05), and therefore displayed the predictive validity which 
was expected. Gluten consumption at any level did not have any statistically 
significant effects upon gastrointestinal symptoms, which reflects the uncertainty 
about its causative role in GI symptoms. Therefore, the low expectation of significant 
results for the association between gluten consumption and gastrointestinal symptoms 
due to the conflicting literature also displayed the predictive validity which was 
expected. 
5.5 Participant’s fibre, gluten and FODMAP intake 
The fibre, gluten, and FODMAP intake of the participants did not significantly differ 
between each of the IBS subtypes. There were no significant differences between the  
participants’ fibre intake according to IBS subtype. Fibre intake was highest for 
participants in the IBS-C subtype, consuming 1.6-2.0g more than IBS-D and IBS-M 
participants. Both male participants consumed a mean daily fibre intake of 32g, 
meeting the Ministry of Health nutrient reference value recommendation of 30g per 
day for males (83). The women consumed a mean daily intake of 23g of fibre, which 
is below the recommended 25g of fibre per day for women (83). Participants 
consumed a mean intake of 23.6(±7.2) grams of fibre daily. This is illustrated in 
Figure 5.1 and detailed in Table 5.5 below.  
Table 5.5 The distribution of participants according to IBS subtype and the mean 
daily intake of fibre (grams) per participant group 
 IBS-C (n=11) IBS-D (n=22) IBS-M (n=18) All (n=51)1 p-value 
Daily fibre 1 25.0g (10.2) 23.4g (6.0) 23.0g (7.0) 23.6g (7.2) 0.9033 
Low fibre intake 2 5 (45.5) 7 (31.8) 5 (27.8) 16.0g (2.4)  
0.8254 Medium fibre 
intake 2 
2 (18.2) 8 (36.4) 7 (38.9) 23.1g (2.5) 
High fibre intake 2 4 (36.4) 7 (31.8) 6 (33.3) 31.7g (4.5) 
1 Data expressed as mean (standard deviation). 
2 Data expressed as n (%). 
3 ANOVA,  p <0.05 is considered statistically significant 
4 Fishers exact test, p <0.05 is considered statistically significant 
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Figure 5.1 Mean daily fibre intake (grams) per participant according to IBS subtype 
 
Participants consumed a mean 3.8 servings of gluten-containing foods daily (see 
Figure 5.2).  Those with IBS-M consumed the most servings (4.2 servings daily), 
while IBS-D and IBS-C participants consumed 3.9 and 3.0 servings, respectively. 
There was no statistically significant difference between the gluten-containing food 
servings consumed by each IBS subtype.  
 
Figure 5.2 Mean daily servings of gluten containing foods consumed per participant 
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The mean daily intake of high FODMAP foods according to IBS subtype and 
participant is illustrated in Figure 5.3. Participants consumed a mean daily intake of 
5.9 high FODMAP foods. Those with IBS-D consumed the least, 5.7 high FODMAP 
foods daily, while those with IBS-M consumed the most, 6.2 high FODMAP foods 
daily. Participants with IBS-C consumed 5.8 high FODMAP foods daily.  
 
Figure 5.3 Mean daily intake of high FODMAP food items per participant according 
to IBS subtype 
 
 
5.6 Questionnaire about the diary 
98% of participants reported understanding how to complete the food and symptom 
diary. The one participant who reported they did not understand how to complete the 
food and symptom diary was only uncertain whether to note other symptoms such as 
nausea that weren’t mentioned in the diary. Ten participants, of various ages, 
ethnicities and IBS subtype, responded that the food and symptom diary caused too 
much inconvenience, due to the high respondent burden commonly associated with 
food diaries in general. All participants reported they were perfectly or mostly 
accurate in reporting food and beverage intake, and 92% of participants were perfectly 
or mostly accurate in reporting symptoms. Improvements to the diary suggested by 
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gastrointestinal symptoms of nausea and anxiety in the diary, having a digital version 
of the diary, a section to report water consumed in drink bottles periodically 
throughout the day, and including consecutive days of diary reporting. 75% of 
participants found that the diary helped them to get a better understanding of how 
food affected their symptoms.  
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6. Discussion 
 
Unlike the majority of studies assessing gastrointestinal symptoms in IBS, the present 
study has the advantage of providing a novel real-time gastrointestinal symptom scale 
that accurately records the symptoms experienced by participants as they occur. This 
is the first study that has used real-time symptom scales to assess gastrointestinal 
symptoms in adults with IBS. The results show that the real-time gastrointestinal 
symptom scales show moderate validity for the severity and for the length of time the 
gastrointestinal symptoms were experienced. The participant’s food intake did not 
differ significantly according to IBS subtype. Consuming lesser amounts of 
FODMAPs was significantly associated with less severe bloating; and consuming 
fibre was inversely associated with the severity of abdominal pain prior to a bowel 
motion, as well as the severity of straining to have the bowel motion, which both 
displayed the predictive validity expected, based on current accepted knowledge.  
 
The median severity of each gastrointestinal symptom experienced was ‘not bad at 
all’ to ‘a little bad’. The mild severity of these gastrointestinal symptoms experienced 
is much less severe than found in other IBS populations (2, 46, 47, 70). The mild 
severity of all symptoms experienced by participants during this study might be due to 
the small sample size of this pilot study, or be due to participants reporting symptoms 
in real-time and not relying on recall to report symptoms retrospectively. It is 
important to note that while the majority of participants were mostly accurate in 
reporting their symptoms, entering in symptoms at the end of the day, back-filling, 
may have occurred. Research has found that reporting symptoms in real time or at the 
end of the day is more accurate than recalling symptoms from the past week due to 
over-reporting which occurs (6, 77). In line with this, the mild severity of the 
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gastrointestinal symptoms experienced may have acted as a floor effect (84) resulting 
in weak to moderate correlations with the legacy instruments. Another possibility is 
that medicines and/or nutritional supplements may have been used to reduce the 
severity of symptoms. Investigation of these possible confounders was outside the 
scope of this thesis, but should be considered by the COMFORT study researchers. As 
participants were deemed eligible for the study based on the symptoms of abdominal 
pain and bowel motions in the Rome IV criteria described in section 4.3.2, it is hardly 
surprising that abdominal pain was the most common and severe symptom 
experienced in the study.  
 
Several studies have validated retrospective questionnaires to assess gastrointestinal 
symptoms (3-5, 45-47). However, the focus of the current study was to validate a real-
time food and symptom diary which concurrently records gastrointestinal IBS 
symptoms as they occur along with the intake of food and beverages. To establish 
construct validity of the real-time gastrointestinal symptom scales as an indicator of 
gastrointestinal symptom severity and occurrence, correlation coefficients were used 
to investigate the relationship between selected relevant symptom scales and 
questions from the legacy instruments the GSRS, the PROMIS GI scales, and the IBS-
QOL to the symptom scales incorporated into the three-day food and symptom diary.  
 
In our study, the majority (62.7%) of the real-time gastrointestinal symptom scales 
had statistically significant Spearman’s correlation coefficients between 0.3 and 0.7 
when compared to the legacy instruments the GSRS, the PROMIS GI scales, and the 
IBS-QOL. Previous research has found correlation coefficients of 0.3-0.6 to show 
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good construct validity when assessing associations between questionnaires assessing 
gastrointestinal symptoms (4, 5, 45, 48).  
 
There are several possible explanations for the level of validity of the real-time 
gastrointestinal symptom scales. As IBS-C was the least populous IBS subtype in the 
present study, this may account for the lack of significance when comparing the 
legacy instrument’s constipation scales to the real-time gastrointestinal symptoms. 
The real-time gastrointestinal symptom scales are a patient-reported outcome 
measure, therefore the stronger correlation to the PROMIS GI scales than the other 
legacy instruments is not unexpected. The reputable modern psychometric 
construction of the PROMIS GI scales (4) make it the most advantageous legacy 
instrument to have the strongest correlations with the real-time gastrointestinal 
symptom scales. As the legacy instruments reported symptoms retrospectively over 
the past week or month, it is not surprising that these measures have lower 
correlations with the length of time the real-time gastrointestinal symptoms were 
experienced than for their severity, as the timescale they cover differs from 7 to 30 
days compared to the exact minutes to hours the symptoms were experienced as 
reported in the diary. Comparing minutes per day of symptoms experienced to the 
legacy instruments asking about the past week or months symptoms is not necessarily 
prudent – future research should test scaling the length of time symptoms were 
experienced; this may be especially important to compare associations between food 
intake at meals and subsequent IBS symptoms in the following hours. As the real-time 
gastrointestinal symptoms are recorded as they occur instead of reporting 
retrospective symptoms, modest correlations to the legacy instruments were expected 
due to symptom fluctuation throughout the day, and their reliance on memory recall. 
    45 
The real-time gastrointestinal symptom scales are likely to be more accurate in 
reporting symptom occurrence and severity due to symptoms being recorded in the 
diary as they occur and not relying on long-term memory (73). Minimising the 
participant’s recall bias in this way improves the accuracy of participant reporting of 
both their food intake and gastrointestinal symptoms.  
 
Seventeen study participants (including the two males) recorded adequate fibre intake. 
This leaves 34 female study participants that are not meeting the adequate intake of 
25g of fibre per day recommended for NZ female adults (83). While the study 
participants are consuming more fibre than the general adult population of NZ (17.5g 
and 22.1g daily for females and males respectively) (85), this suggests that despite the 
traditional advice for IBS patients to increase their fibre intake, many study 
participants are not meeting their fibre needs through food alone, if at all. Information 
about the use of nutritional supplements was not collected for this study, therefore it is 
possible participants were taking nutritional fibre supplements to meet their fibre 
requirements. As fibre affects gastrointestinal transit, it is typically prescribed to 
relieve symptoms of constipation. While evidence surrounding fibre consumption in 
IBS is conflicting, it has been linked to relieving the symptoms of constipation, 
bloating, and abdominal discomfort and worsening the symptoms of diarrhoea and 
bloating (13-17). In the present study, fibre was found to inversely affect abdominal 
pain prior to a bowel motion, and straining to have the bowel motion, symptoms 
commonly related to constipation. This study had a low percentage of IBS-C 
participants, perhaps a larger follow-up study, with greater diversity of IBS subtypes, 
using the food and real-time gastrointestinal symptom diary to explore the effects of 
fibre will increase the understanding of the conflicting role fibre has in treating IBS.  
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Gluten consumption was not found to be associated with the real-time gastrointestinal 
symptoms. It should be noted that as the exact quantities of gluten and FODMAPs 
consumed by participants could not be determined in this study, these dietary factors 
were unable to be controlled. While gluten consumption has been associated with 
adverse gastrointestinal symptoms, double blind randomised control trials of IBS 
participants have had conflicting results, and several did not control for dietary 
factors. In patients with non-coeliac gluten sensitivity, previous research found gluten 
to have no effect upon IBS symptoms while consuming a low FODMAP diet (21) 
Conversely, an earlier study not controlled for dietary confounders such as 
FODMAPs, found that gluten increased gastrointestinal symptoms (18). Other 
researchers have found gluten to be associated with increased stool frequency in IBS-
D participants, however dietary factors were again not controlled for (19). At this 
point, based on the results of this study and prior research, there is insufficient 
evidence to make a recommendation for a gluten-free diet to treat IBS symptoms.  
 
In the present study, high FODMAP consumption was found be associated with 
increased severity of abdominal bloating.  A proposed mechanism of this action is 
luminal distension caused by the fermentation of FODMAPs by colonic bacteria (22). 
Previous research has shown high FODMAP consumption to be associated with 
abdominal pain, bloating and diarrhoea in IBS patients (22-24, 71). In the current 
study however, perhaps due to the collation of tertiles of daily FODMAP intake to 
investigate the relationship with gastrointestinal symptoms, these effects were not 
seen. Participants may simply avoid FODMAP-containing foods that trigger IBS 
symptoms. The FODMAP content of the food items consumed could not be precisely 
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determined in this study, instead the food items were allocated as containing high, 
medium, or low FODMAPs and then collated into tertiles of mean daily intake. Future 
research should investigate the association between precise amounts of FODMAP 
consumption and subsequent gastrointestinal symptoms using a food and nutrient 
database containing FODMAPs.  
 
To confirm the participant’s IBS diagnosis, participants were eligible for inclusion in 
the study only if they fulfilled the Rome IV criteria developed for use in research, 
ensuring all participants had active IBS. There was some ethnic diversity in our study, 
however not at levels representative of the NZ population. Data collected in the 2013 
census found 14.9% of NZ identified as Maori, 7.4% as Pacific peoples, and 74.0% as 
European, compared to this study with 11.8% Maori, 0% Pacific peoples, and 72.6% 
European (86). While IBS is typically more prevalent in females compared to males 
(26), it is noteworthy that most (96.1%) of the participants in this study were female. 
One should be cautious when applying the conclusions and results drawn here to male 
IBS patients, or indeed to Pacific peoples or other ethnicities not represented in this 
study. This study might have reduced selection bias better, by recruiting from sports 
groups, churches, and school newsletters, to capture participants of more diverse 
ethnicities and hopefully more males.  
 
Weighed food records, the gold standard in dietary assessment, have a high 
respondent burden; therefore to reduce this burden and improve the participant’s 
response rate, estimated food records were incorporated into the food and symptom 
diary (25). There was a high response rate of 78.5% completing the study, despite 10 
participants believing the diary caused too much inconvenience for reasons common 
    48 
to all food diaries. Three non-consecutive days were recorded, enabling an estimation 
of the participant’s habitual intake. To ensure participants understood how to 
complete the diary, detailed written and verbal instructions explaining how to record 
and accurately estimate food and beverage consumption, and symptoms duration and 
frequency, were given to each participant. The food and nutrient analysis programme 
Kai-culator, used to analyse the food and beverage intakes of the participants, 
contains a large database of NZ-specific food items and recipes. All diaries were 
entered by the candidate using a standard protocol, reducing any interpersonal error. 
After data entry, the diaries were additionally checked by an experienced dietitian for 
any data anomalies.  
 
The present study investigated the relationship between daily symptoms and the 
consumption of fibre, gluten and FODMAPs according to tertiles of intake. Kai-
culator does not contain gluten or FODMAP content. While great care was taken to 
allocate food items according to their gluten and FODMAP content, the nutrient 
content of these items may be underreported because the exact amount of the nutrients 
gluten and FODMAPs the food items contained is not known. To get a clearer 
understanding of this relationship, future research should investigate the associations 
between the precise amounts of the nutrients gluten and FODMAPs consumed and 
gastrointestinal symptoms, using a database containing these nutrients. Further 
research should also examine the effect of consuming precise amounts of these 
nutrients upon subsequent gastrointestinal symptoms in the following hours instead of 
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6.1 Conclusion 
This pilot study provided some preliminary findings on the predictive validity and 
relative validity of the real-time gastrointestinal symptom scales. Whilst there is some 
evidence that the food and real-time gastrointestinal symptom scales may predict the 
intake of selected nutrients hypothesised to associate with gastrointestinal symptoms, 
to ensure the reliability of these associations, future use of the diary in larger 
populations is required. The real-time gastrointestinal symptom scales are a novel 
measure that discriminates by symptom severity and frequency in IBS participants 
and have been validated using a construct validity process; the real-time 
gastrointestinal symptom scales show moderate correlations to the retrospective 
legacy instruments the GSRS, the PROMIS GI scales, and the IBS-QOL. 
Nevertheless, future research is recommended to examine the role of diet upon IBS 
symptoms using a food and nutrient database which contains gluten and FODMAPs, 
to increase the knowledge and options for the dietary management of IBS symptoms.  
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7. Application to Practice 
 
The majority of IBS patients believe that certain food items can cause or worsen their 
gastrointestinal symptoms (11). Despite this, there is conflicting evidence surrounding 
the role of diet in the treatment and management of IBS symptoms. To increase the 
knowledge and options for the dietary management of IBS symptoms, this thesis has 
focused on validating a real-time gastrointestinal symptom scale incorporated into a 
three-day food diary.  
 
This study has provided a novel food and validated real-time gastrointestinal symptom 
diary for use in IBS patients. Investigation has found that consuming more fibre is 
associated with less severe abdominal pain prior to bowel motions and with less 
severe straining prior to having a bowel motion. It has also supported that a high 
FODMAPs consumption is associated with more severe abdominal bloating than 
those consuming lesser amounts of FODMAPs.  
 
Dietitians can have a fundamental role in alleviating these gastrointestinal symptoms, 
using evidence-based practice to support the optimal well-being of IBS patients (12, 
87). This food and symptom diary will be useful in clinical practice to determine 
which food items may cause or worsen gastrointestinal symptoms, enabling the 
provision of patient-centred care.  Dietitians will be able to give patient-specific 
dietary guidance on which foods to exclude to improve symptom management, while 
ensuring patients are able to achieve a well-balanced diet. 
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Appendix C: Demographic Questionnaire (size and formatting changed 
for binding)   
 
Welcome to our questionnaire about the short-term food and symptom diary for patients  
with irritable bowel syndrome. In this survey, you will be asked questions about your  
symptoms. The questionnaire will take approximately 10 minutes to complete. 
 
Your participation in this study is completely voluntary. There are no foreseeable risks  
associated with this project. However, if you feel uncomfortable answering any  
questions, you can withdraw from the survey at any point.  
 
Your survey responses will be coded and will remain confidential. If you have questions  
about the survey or procedures, please email foodandsymptomdiary@outlook.co.nz. 
 
Thank you very much for your time and support.  
 
 
Please state your email address. This is required to send you the results of the project.  














Q3. Are you descended from a Māori (that is, did you have a Māori birth parent,  
       grandparent or great-grandparent, etc.)? 
 ☐ Yes 
 ☐ No 
 ☐ Don't know 
 
Q4. Which ethnic group do you belong to? (Please tick the box(es) which apply to you) 
 ☐ New Zealand European 
 ☐ Māori 
 ☐ Samoan 
 ☐ Cook Island Māori 
 ☐ Tongan 
 ☐ Niuean 
 ☐ Chinese 
 ☐ Indian 
 ☐ Other, such as Dutch, Japanese, Tokelauan. Please specify:  __________ 
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Q5. Please indicate if you have any of the following conditions. (Please tick the box or 
       boxes which apply to you): 
 ☐ Stroke 
 ☐ Cancer or tumour 
 ☐ Diabetes Type 1 
 ☐ Diabetes Type 2 
 ☐ Epilepsy 
 ☐ Blood disorder/diseases e.g. hepatitis  
 ☐ Other (please specify): __________ 
 ☐ None of the above 
 
Q6. Have you been diagnosed with any gastrointestinal disorder other than irritable  
       bowel syndrome? (i.e. coeliac disease, inflammatory bowel disease, diverticulosis) 
 ☐ Yes 
 ☐ No 
 
Q7. Please name the gastrointestinal disorder(s) you have been diagnosed with.  
 ☐ Crohn's Disease 
 ☐ Ulcerative Colitis 
 ☐ Coeliac Disease 
 ☐ Colorectal Cancer 
 ☐ Bowel Resection 
 ☐ Diverticulosis (Diverticular Disease) 
 ☐ Other (please specify): __________ 
 







Q9. Are you currently taking laxatives?  
 ☐ Yes 
 ☐ No 
 
Q10. How often do you take laxatives? 
 ☐ Daily 
 ☐ Weekly 
 ☐ Monthly 
 ☐ Less than monthly 
 
Q11. Do you smoke? 
 ☐ Yes 
 ☐ No, I never did 
 ☐ No, but I used to 
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Q12. Do you drink any alcohol? (if yes please select from frequency options below.  
         Please note that one standard drink equals one unit) 
 ☐ No 
 ☐ Yes, less than 5 units per week 
 ☐ Yes, between 5 and 14 units per week 
 ☐ Yes, between 14 and 21 units per week 






































    70 
Appendix D: Rome IV Diagnostic Questionnaire for Adults, Irritable 
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SCORING OF THE ROME IV IRRITABLE BOWEL SYNDROME MODULE 
 
C1. IRRITABLE BOWEL SYNDROME 
Must fulfill the following criteria for the past 3 months:  
1. Recurrent abdominal pain  
Q40 = at least weekly 
2. Pain is associated with two or more of the following criteria: 
a. Related to defecation 
Q41 = at least 30% of occasions 
b. Associated with a change in frequency of stool 
Q42 = at least 30% of occasions 
c. Associated with a change in form (appearance) of stool 
Q43 = at least 30% of occasions 
3. Symptom onset at least 6 months prior to diagnosis  
                Q48 = yes 
 
    IBS Subtypes 
When using the Rome IV Diagnostic Questionnaire, IBS subtypes are based on 
patient perception of the usual consistency of abnormal stools. Question 64 uses a 
picture of the Bristol Stool Scale to define abnormal stools and to classify them as 
follows: 
     IBS-C if abnormal stools are usually constipation (types 1-2),  
     IBS-D if abnormal stools are usually diarrhea (types 6-7),  
     IBS-M if abnormal stools are mixed with at least 1/4 constipation  
         AND at least 1/4 diarrhea, 
     IBS-U if the subject never or rarely has abnormal stools  
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Appendix E: Example of the Food and Symptom Diary (size and 


























Food and Symptom 
Diary 
Different eating patterns have an effect on people’s health.  
To help us understand these eating patterns we would like 
you to complete this estimated food diary.  You need record 
all food and drink that you consume on three non-
consecutive days. 
 
If you have any questions regarding this questionnaire 
please contact Morag Wright-McNaughton at 
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How to describe your food and drink using household 
measures 
 
Below are some suggestions on how to describe certain food and drink items together 
with their household measures. 
Food Description of food or drink and brand 
Household 
measure 
Bacon Shoulder or streaky; fried or grilled rashers, 
smoked or unsmoked 
Number 
Bread Type of bread, e.g. white, brown, wholemeal, 
granary, French stick, ciabatta, currant. 





Type, brand name 
For example: 335ml can Diet Coca Cola 
Number or 
full or half 
can 
Crisps Type, brand name e.g. 30g Rashuns Packet 
weight 
Fruit Type and size of fruit e.g. large Granny Smith 
apple 





Jams Type, brand name e.g. Pam’s strawberry jam Teaspoons, 
heaped or flat 
Milk Type; full cream, trim, semi-trim Pints, glasses 
or cups 
Oil Type e.g. canola oil, sunflower oil, corn oil, olive 





Full name of product including brand name. 
For example: Bird’s Eye fish fingers.  
Keep the package. 
Number 
Sandwich Describe fully if homemade or if bought; 
Full name, place of purchase and price, 
describe bread as above and note loaf size. 
Number of 
slices of 




Type e.g. butter, low fat spread, rice bran oil 
spread, canola spread, reduced fat canola 
spread, Weightwatchers spread.  
Full description, and brand name  






Sugar Type e.g. caster, rich brown, white Teaspoons, 




Name, size (weight) and price (if known) 
For example: king size Mars bar 99c 
Keep the wrapper 
Weight of bar 
or number of 
sweets 
Takeaways Describe in full, give name of restaurant  
For example:  One scoop chips, The High Street 
chip shop. Standard chicken chow mein 
Portion size 
and price 
Vegetables Type; fresh, frozen, tinned or dried 
Brand name 
Tablespoons, 
full or heaped  
Adapted from NUGENOB study (www.nugenob.com)
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  Sample record sheet 
Please record all food and drink consumed during the whole day, including snacks and water. 























Please record brand names e.g. McCoy. Please use household measures to describe amounts of food such as      





Food or Drink Brand and details Preparation/ 
Cooking 
Quantity 
A 8 am In bed Alone Gourmet muffin New World – double 
chocolate  
None 1 
    Coffee Nescafe instant, 
Sugar 
Green top milk  
Hot water added 1 heaped teaspoon in 
a mug, 1 heaped 
teaspoon, 1/8th of mug 
B 10 am  Kitchen Family Tea Twinings Peppermint Hot water added 1 mug, no milk/sugar 
    Biscuits Tim Tam Double 
Chocolate 
None 2 
C 12pm   Tuna pasta Homemade recipe 1 Pasta boiled in water 1/3 recipe 
    French bread  Bought–New World  6cm long 
    Margarine Pams–Canola low salt  1 level tsp 
    Chicken breast Skin & bone removed Fried in olive oil 1 medium 
    Olive oil Luppi Fried ½ tbsp 
    Cherry tomato  Raw 2  
    Orange juice McCoy, unsweetened  200ml 
D 5.30pm McD’s 
 
Son Burger, Fries, 
Diet Coke 
McD’s Big Mac (no 
pickles) 
 1burger, large fries & 
coke 
E 6.30pm Home  Friend Beer Monteiths Radler  2 bottles 
    Toast Vogels Rice and Rye Toasted 2 slices 
    Margarine Pams–Canola low salt  1 level tsp 
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1 
Live Gastrointestinal Symptom score (LGS) 
 
 
Over the next three days when you are recording what you are eating 
in the diet diary, we would like to understand your gastrointestinal 
symptoms in detail. At the top of each page please mark using letters 




We would like you to use this record to tell us whether you have 
specific symptoms and, if so, when you noticed them and how bad 
they were. There are five symptoms that we would like you to 
comment on: 
 
1. Abdominal pain 
 
2. Abdominal swelling/distension 
 
3. Abdominal fullness 
 
4. Abdominal bloating 
 
5. Bowel motion frequency 
 
Each question includes a 24 hour time scale and a tick box to indicate if 
you have not experienced that particular symptom. 
 
For example: the first time scale is about abdominal pain. If you did suffer 
from pain, please mark the time that the pain started and stopped on the 
24-hour time scale. Between these two marks, please write the number 
between 1 and 5 which best reflects the severity of the pain. 
 
1) Not bad at all    2) A little bad   3) Somewhat bad    4) Quite bad   
5) Very bad 
 
 
If you had multiple episodes of abdominal pain over the 24-hour period, 
please mark each one on the 24 hour time scale, with the severity of pain 
between each mark. Please see the example below: 
 3 
A B C E D 
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When Where Who 
with 
Food or Drink Brand and details Preparation/ 
Cooking 
Quantity 
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Diet Diary Day … continued                       Date_____________________ 
Meal 
 
When Where Who 
with 
Food or Drink Brand and details Preparation/ 
Cooking 
Quantity 
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Please mark on the scale if you had any of the symptoms over the 
last 24 hours, and write the severity of the symptoms using the 
following scale:  
 
1.Not bad at all 2.A little bad 3.Somewhat bad 4.Quite bad 5.Very bad 
 
Symptom 1. Abdominal pain    None       ☐  




Symptom 2. Abdominal swelling/distension None       ☐ 
    
 
 
Symptom 3. Abdominal fullness   None       ☐ 
    
 
 
Symptom 4. Abdominal bloating   None       ☐ 
    
 
 
If you had a Bowel Motion in the last 24 hours please mark on  
the scale. If you didn’t please tick the box.   
Bowel motions    No bowel motions      ☐ 
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How much did you strain to pass the bowel motion? 
6. Not at all 
7. Slightly strain 
8. Moderately strain 
9. Significantly strain 
10. Unable to empty bowel 
 
Did you have abdominal pain before your bowel motion? 
6. No abdominal pain 
7. Not bad at all 
8. A little bad 
9. Somewhat bad 
10. Quite bad 
11. Very bad 
 
How much urgency do you experience when you need to have a bowel 
motion? 
1. Not at all 
2. A little urgency 
3. I have to hurry 
4. I have to go immediately 
5. I am incontinent (unable to control the urge and had an accident) 
How much did you strain to pass 
the bowel motion? 
1. Not at all 
2. Slightly strain 
3. Moderately strain 
4. Significantly strain 
5. Unable to empty bowel 
 
Did you have abdominal pain 
before your bowel motion? 
0. No abdominal pain 
1. Not bad at all 
2. A little bad 
3. Somewhat bad 
4. Quite bad 
5. Very bad 
 
How much urgency do you 
experience when you need to 
have a bowel motion? 
1. Not at all 
2. A little urgency 
3. I have to hurry 
4. I have to go immediately 
5. I am incontinent (unable to 
control the urge and had 
an accident) 
Bowel Motion Chart Day …     
  
Please complete the following chart reporting symptoms with each 



























 BM1 BM2 BM3 BM4 BM5 BM6 BM7 BM8 BM9 
Bristol stool type 
(please write the 
number) 
         
How much did 
you strain? 
(please write the 
number) 
         
Abdominal pain 
before BM? 
(please write the 
number) 
         
Urgency? (please 
write the number) 
         
Abdominal pain 
relieved by BM? 
(Yes/ No/ N/A) 




(Yes/ No/ N/A) 
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Recipes 
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Are there any special reasons why this week may differ from ‘normal’ in terms 
of household food (for example a child’s birthday party or other family 
celebration)?   
 
Please circle either Yes or No 
 





Please check that you have filled in your food and symptom diary for all 
three days. Please make sure that you have answered all the symptom 
questions.  
 
Don’t forget to include any: 
- Drinks e.g. tea, coffee, wine, beer, orange juice, soft drinks, 
water 
- Snacks between meals e.g. biscuits, crisps, peanuts, slices, 
muffins 
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Appendix F: Questionnaire about the diary 
Questionnaire about the Food and Symptom diary  
  
Please answer the questions below HONESTLY. It is important we figure out how to  
make this diary the best way we can.  
  
1. Did you understand how to complete the food and symptom diary?  
Yes  



















3. Do you feel you were accurate in reporting your food and beverage intake?  
Perfectly accurate  
Mostly accurate  
Somewhat accurate  
Inaccurate  
  
4. Do you feel you were accurate in reporting your symptoms?  
Perfectly accurate  
Mostly accurate  
Somewhat accurate  
Inaccurate  
  
5. How could the food and symptom diary be made better? (write a few  











6. Did you feel keeping the diary helped you get an understanding of how food 






    88 
Appendix G: Gastrointestinal Symptom Rating Scale (formatting 
changed for binding) 
 




 Please read this first: 
 
 This survey contains questions about how you have been feeling and  
        what it has been like DURING THE PAST WEEK. Mark the choice that  




1. Have you been bothered by PAIN OR DISCOMFORT IN YOUR UPPER  
 ABDOMEN OR THE PIT OF YOUR STOMACH during the past week? 
 
  No discomfort at all 
  Minor discomfort 
  Mild discomfort 
  Moderate discomfort 
  Moderately severe discomfort 
  Severe discomfort 
  Very severe discomfort 
 
 
2. Have you been bothered by HEARTBURN during the past week? (By  
           heartburn we mean an unpleasant stinging or burning sensation in the  
           chest.) 
 
  No discomfort at all 
  Minor discomfort 
  Mild discomfort 
  Moderate discomfort 
  Moderately severe discomfort 
  Severe discomfort 
  Very severe discomfort 
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3. Have you been bothered by ACID REFLUX during the past week? (By acid  
           reflux we mean the sensation of regurgitating small quantities of acid from  
           the stomach up to the throat.) 
 
  No discomfort at all 
  Minor discomfort 
  Mild discomfort 
  Moderate discomfort 
  Moderately severe discomfort 
  Severe discomfort 
  Very severe discomfort 
 
 
4. Have you been bothered by HUNGER PAINS in the stomach during the past  
           week? (This hollow feeling in the stomach is associated with the need to eat  
           between meals.) 
 
  No discomfort at all 
  Minor discomfort 
  Mild discomfort 
  Moderate discomfort 
  Moderately severe discomfort 
  Severe discomfort 
  Very severe discomfort 
 
 
5. Have you been bothered by NAUSEA during the past week? (By nausea we  
           mean a feeling of sickness that may lead to retching and vomiting.) 
 
  No discomfort at all 
  Minor discomfort 
  Mild discomfort 
  Moderate discomfort 
  Moderately severe discomfort 
  Severe discomfort 
  Very severe discomfort 
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6. Have you been bothered by RUMBLING in your stomach during the past  
           week? (Rumbling refers to vibrations or noise in the stomach.) 
 
  No discomfort at all 
  Minor discomfort 
  Mild discomfort 
  Moderate discomfort 
  Moderately severe discomfort 
  Severe discomfort 
  Very severe discomfort 
 
 
7. Has your stomach felt BLOATED during the past week? (Feeling bloated  
           refers to swelling often associated with a sensation of gasses in the                  
           stomach.) 
 
  No discomfort at all 
  Minor discomfort 
  Mild discomfort 
  Moderate discomfort 
  Moderately severe discomfort 
  Severe discomfort 
  Very severe discomfort 
 
 
8. Have you been bothered by BELCHING during the past week? (Belching  
           refers to the release of wind from the stomach via the mouth, often 
           associated with easing a bloated feeling.) 
 
  No discomfort at all 
  Minor discomfort 
  Mild discomfort 
  Moderate discomfort 
  Moderately severe discomfort 
  Severe discomfort 
  Very severe discomfort 
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9. Have you been bothered by BREAKING WIND during the past week?  
           (Breaking wind refers to the need to release air or gas from the bowel,  
           often associated with easing a bloated feeling.) 
 
  No discomfort at all 
  Minor discomfort 
  Mild discomfort 
  Moderate discomfort 
  Moderately severe discomfort 
  Severe discomfort 
  Very severe discomfort 
 
 
10. Have you been bothered by CONSTIPATION during the past week?  
           (Constipation refers to a reduced ability to empty the bowels.) 
 
  No discomfort at all 
  Minor discomfort 
  Mild discomfort 
  Moderate discomfort 
  Moderately severe discomfort 
  Severe discomfort 
  Very severe discomfort 
 
 
11. Have you been bothered by DIARRHOEA during the past week? (Diarrhoea  
           refers to a too frequent emptying of the bowels.) 
 
  No discomfort at all 
  Minor discomfort 
  Mild discomfort 
  Moderate discomfort 
  Moderately severe discomfort 
  Severe discomfort 
  Very severe discomfort 
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12. Have you been bothered by LOOSE STOOLS during the past week? (If your  
           stools (motions) have been alternately hard and loose, this question only  
           refers to the extent you have been bothered by the stools being loose.) 
 
  No discomfort at all 
  Minor discomfort 
  Mild discomfort 
  Moderate discomfort 
  Moderately severe discomfort 
  Severe discomfort 
  Very severe discomfort 
 
 
13. Have you been bothered by HARD STOOLS during the past week? (If your  
           stools (motions) have been alternately hard and loose, this question only  
           refers to the extent you have been bothered by the stools being hard.) 
 
  No discomfort at all 
  Minor discomfort 
  Mild discomfort 
  Moderate discomfort 
  Moderately severe discomfort 
  Severe discomfort 
  Very severe discomfort 
 
 
14. Have you been bothered by an URGENT NEED TO PASS YOUR MOTIONS 
 during the past week? (This urgent need to go to the toilet is often 
           associated with a feeling that you are not in full control.) 
 
  No discomfort at all 
  Minor discomfort 
  Mild discomfort 
  Moderate discomfort 
  Moderately severe discomfort 
  Severe discomfort 
  Very severe discomfort 
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15. When going to the toilet during the past week, have you had the  
           SENSATION OF NOT COMPLETELY EMPTYING THE BOWELS? (This 
feeling  
           of incomplete emptying means that you still feel a need to pass your  
           motions despite having exerted yourself to do so.) 
 
  No discomfort at all 
  Minor discomfort 
  Mild discomfort 
  Moderate discomfort 
  Moderately severe discomfort 
  Severe discomfort 







PLEASE CHECK THAT ALL QUESTIONS HAVE BEEN ANSWERED! 
 
THANK YOU FOR YOUR CO-OPERATION. 
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Appendix H: Irritable Bowel Syndrome Quality of Life questionnaire 
(formatting changed for binding) 
 
   
    PLEASE WRITE IN 
 TODAY'S DATE: ____    ______     _____ 






PLEASE READ THIS CAREFULLY 
 
ON THE FOLLOWING PAGES YOU WILL FIND STATEMENTS CONCERNING BOWEL 
PROBLEMS (IRRITABLE BOWEL SYNDROME) AND HOW THEY AFFECT YOU. 
 
FOR EACH STATEMENT, PLEASE CHOOSE THE RESPONSE THAT APPLIES BEST TO YOU  
AND CIRCLE THE NUMBER OF YOUR RESPONSE. 
 
IF YOU ARE UNSURE ABOUT HOW TO RESPOND TO A STATEMENT, PLEASE GIVE THE 
BEST RESPONSE YOU CAN. THERE ARE NO RIGHT OR WRONG RESPONSES.  
 




IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT: 
 














The Irritable Bowel Syndrome-Quality of Life questionnaire (IBS-QOL) was developed by Donald L. Patrick, 
Ph.D. at The University of Washington, Douglas A. Drossman, MD at The University of North Carolina, 
Novartis Pharmaceuticals Corporation, and Novartis Pharma AG. Authors hold joint copyright over the IBS-





This is about how you feel 
 
Please think about your life over the past month (last 30 days), and look at the 
statements below.  Each statement has five possible responses.  For each statement, 
please circle the one response that best describes your feelings. 
 
 
1. I feel helpless because of my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
2. I am embarrassed by the smell caused by my bowel problems. (Please circle 
one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
3. I am bothered by how much time I spend on the toilet. (Please circle one 
number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
4. I feel vulnerable to other illnesses because of my bowel problems. (Please 
circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
5. I feel fat/bloated because of my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
5 A GREAT DEAL 
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6. I feel as though I'm losing control of my life because of my bowel problems. 
(Please circle one number)  
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
7. I feel that my life is less enjoyable because of my bowel problems. (Please 
circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
8. I feel uncomfortable when I talk about my bowel problems. (Please circle one 
number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
9. I feel depressed about my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
10. I feel isolated from other people because of my bowel problems. (Please 
circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
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11. I have to be careful about the amount of food I eat because of my bowel 
problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
12. Sexual activity is difficult for me because of my bowel problems. (Please 
circle one number) 
 (If not applicable, please circle “NOT AT ALL”) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
13. I feel angry that I have bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
14. I feel as though I irritate other people because of my bowel problems. (Please 
circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
15. I worry that my bowel problems will get worse. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
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16. I feel irritable because of my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
17. I worry that people think I exaggerate my bowel problems. (Please circle one 
number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
18. I feel I get less done because of my bowel problems. (Please circle one 
number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
19. I have to avoid stressful situations because of my bowel problems. (Please 
circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
20. My bowel problems reduce my sexual desire. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
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21. My bowel problems limit what I can wear. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
22. I have to avoid strenuous activity because of my bowel problems. (Please 
circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
23. I have to be careful about the kind of food I eat because of my bowel 
problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
24. Because of my bowel problems, I have difficulty being around people I do not 
know well. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
25. I feel sluggish because of my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
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26. I feel “unclean” because of my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
27. Long trips are difficult for me because of my bowel problems. (Please circle 
one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
28. I feel frustrated that I cannot eat when I want to because of my bowel 
problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
29. It is important to be near a toilet because of my bowel problems. (Please 
circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
30. My life revolves around my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
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31. I worry about losing control of my bowels. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
32. I fear that I won't be able to have a bowel movement. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
33. My bowel problems are affecting my closest relationships. (Please circle one     
            number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
34. I feel that no one understands my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 





Appendix I: Patient Reported Outcomes Measurement Information System 














Belly Pain  
 






































More than once a day  
2 
GISX79 


































Below is a picture showing the front of the body.  The belly is divided into 9 areas, numbered “1” through 
“9.” Please select the numbers that correspond with the areas where you felt your belly pain over the past 
7 days.  You may select more than one number if you had pain in more than one area. 




























































































Very much  
6 
GISX92 

























Constipation   
 
 
























More than once a day  
2 
GISX64 









































































Very much  
5 
GISX67 




















Very much  
6 
GISX68 























































In the past 7 days, how often after a bowel movement did you feel unfinished—that is, that you had not 



































































































Very much  
3 
GISX41 































In the past 7 days, how often did you feel like you needed to empty your bowels right away or else you 




















More than once a day 
5 
GISX43 
In the past 7 days, how much did feeling you needed to empty your bowels right away interfere you’re 




















Very much  
6 
GISX44 
In the past 7 days, how much did feeling you needed to empty your bowels right away bother you? 
 ! 
1 
























Disrupted Swallowing   
 
 
















































































In the past 7 days, how often did you have difficulty swallowing solid foods like meat, chicken or raw 









































































































Fecal Incontinence   
 
 




In the past 7 days, how often did you bowel incontinence—that is, have an accident because you could 




















6-7 days   
2 
GISX46 



















6-7 days   
3 
GISX47 


























































Gas/Bloating    
 
 



























A lot  
2 
GISX95 



























































































































































Very much severe 
8 
GISX101 




















Very much severe 
9 
GISX102 




















































































































































































































Gastroesophageal Reflux   
 
 
Please respond to each question or statement by marking one box. 
1 
GISX2 
In the past 7 days, how often did you have regurgitation—that is, food or liquid coming back up into your 




















More than once a day  
2 
GISX3 




















So much that it filled my entire mouth 
3 
GISX9 












































































More than once a day  
6 
GISX12 





























Look at the picture below. In the past 7 days, how often did you feel burning in the red area shown in the 
picture — that is, behind the breastbone? 




















More than once a day  
8 
GISX21 


















































More than once a day  
10 
GISX24 




















Very much  
11 
GISX25 











































































Very much  
